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Abstract 
Natural products, particularly polyketides are among the most important sources 
of antimicrobial compounds. 20% of the top selling drugs are polyketide based. In recent 
years genetic engineering has played a critical role in modifying biosynthetic pathways of 
different polyketide compounds as a way to create novel structures with improved clinical 
properties. Further investigation and understanding of these giant multi-enzyme complexes 
is necessary to achieve efficient synthetic engineering. 
In many PKS systems including the mupirocin biosynthesis pathway, the 
thioesterase (TE) is normally considered as the end of the assembly line. However, 
expressing the CoA-ligase tmlU from the thiomarinol pathway in the mupirocin producer 
strain (Pseudomonas fluorescens NCIMB10586) revealed that TmlU could only release 
truncated pseudomonic acid when a TE domain was present. This finding led to the 
hypothesis that perhaps the TE domain could act as a tether for TmlU, in order for the 
latter to be able to capture the growing chain and perhaps load it onto the post TE pathway. 
This study also presents the first evidence of MmpB being involved in producing the 9-
hydroxynonanoic acid in the mupirocin biosynthesis pathway. 
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1 Introduction 
1.1 Antibiotics 
 
The concept of using antibacterial compounds to treat wounds and various other 
infections goes back thousands of years, way before the period we consider as “the modern 
antibiotic era”. In Nippur, in the Euphrates valley, circa 2000 BC, a prescription for using 
honey to treat skin infections and ulcers was found written on a clay tablet (Munn and 
Jones, 2001). Other ancient civilizations have also utilized honey and used it for various 
medical applications sometimes combined with other ingredients like red ochre or 
powdered alabaster. Metals have also contributed to the collection of early antibacterial 
agents. Silver for example was used by the settlers of North America to preserve beverages 
like milk, wine and water by dropping silver coins in transport containers (Swathy et al., 
2014). This practice was later modified and used by Japanese soldiers to prevent the spread 
of dysentery (Joseph et al., 2013).  In ancient Rome herbs were used widely as 
antimicrobial agents, Myrrh and barbarum were one of the earliest examples (around 400 
BC) used to treat many septic processes. While the ancient world mostly depended on the 
process of trial and error to discover the therapeutic properties of certain compounds, in 
the 18th century drug discovery started to take a more advanced approach where scientific 
logic and technique were applied to identify possible antimicrobial compounds. One of the 
earliest examples was Edward Jenner’s experiment which paved the way for the use of 
vaccination against some infectious diseases (Timmins, 2009), and then in 1864 Louis 
Pasteur discovered that virus attenuation can be a very useful way to gain protection 
against some viral diseases like Rabies (Enrique Ravina, 2011). However, what we refer to 
as the modern antibiotic era did not start until the early 1900s, when Paul Ehrlich, together 
with chemist Alfred Bertheim and bacteriologist Sahachiro Hata produced Neosalvarsan, a 
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compound that cured syphilis. Ehrlich, in addition to his drug discovery career, also 
pioneered the systematic screening approach on which pharmaceutical companies rely 
upon to this day. The major medical breakthrough though came in 1928 when Alexander 
Fleming noticed that the Staphylococcus aureus he grew on a petri dish contaminated with 
fungus, had lysed and turned translucent instead of their normal yellow opaque colour. The 
fungus was identified as Penicillium notatum and Fleming called the lytic compound 
produced by the mould penicillin (Clardy et al., 2009). Although discovering penicillin 
was a big achievement, the process of isolating and purifying the active substance was a 
tedious task and it was not until 1940 that penicillin was mass produced and distributed to 
pharmaceutical companies using a protocol developed by Howard Florey and Ernest Chain 
that allows penicillin purification in quantities suitable for clinical trials (Aminov, 2010). 
By 1944 Charles Pfizer and Co became the largest producers of penicillin turning out 
100,000 million units a month (Sneader, 2006).  
1.1.1 Antibiotic Targets 
 
Antibiotics can be classified on the basis of their cellular or molecular target into four 
major divisions: inhibitors of DNA replication, RNA synthesis, cell wall synthesis and 
protein synthesis (Walsh, 2003). In order for a bacterial cell to be able to contain 1000 µm 
of double stranded DNA, it has to control the topology of the chromosomal DNA, by 
reducing the space it occupies. In Escherichia coli this is achieved by producing enzymes 
called DNA topoisomerases, of which fluoroquinolones target DNA gyrase and DNA 
topoisomerase IV (Hawkey, 2003).  This class of antibiotics inhibits DNA synthesis by 
interacting with the enzyme-bound DNA complex, forming a drug-enzyme–DNA 
complex. This leads to chromosomal DNA fragmentation and prevents the re-ligation of 
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these fragments, resulting in impaired DNA replication and initiation of the apoptotic 
pathway (Guan et al., 2013) (Schroder et al., 2012). 
RNA synthesis is another valid target for antibiotics like Rifamycins (Floss and Yu, 
2005). It works by binding strongly to the DNA-dependent RNA polymerase during 
initiation, clashing sterically with the growing oligonucleotide. After RNA synthesis has 
progressed to the elongation stage the process is no longer sensitive to the effect of the 
Rifamycins (Artsimovitch and Vassylyev, 2006). 
Given the vital role of the ribosome for the bacterial cellular functions, it is not 
surprising that many clinically relevant antibiotics target different aspects of the ribosomal 
processes as a way to inhibit protein synthesis. The importance of the 30S subunit lies in 
its decoding site (A-site), which monitors codon – anticodon pairing between mRNA and 
tRNA respectively, the function of which is to screen for the accurate match between the 
mRNA codon and the aminoacylated–tRNA anticodon. Among the antibiotics that target 
this site are aminoglycosides, which facilitate amino acid mis-incorporation and 
consequently interfere with translational fidelity (Hermann, 2005). Tetracyclines, in use 
since the 1940s, inhibit protein synthesis by blocking the tRNA binding site (Brodersen et 
al., 2000). By contrast, the antibiotic Pactamycin prevents the formation of the functional 
70S ribosome by causing conformational changes in the 30S subunit and thus blocking the 
tRNA binding site (Brodersen et al., 2000).   Other antibiotics also target the ribosomal 
50S subunit, which contains the peptidyl-transferase centre (PTC), the active site of the 
ribosome, in addition to the peptide exit tunnel (Tenson and Mankin, 2006). 
Chloramphenicol interacts with the PTC and prevents binding to the A-site tRNA. 
Virginiamycin M on the other hand binds to both the A- and P-sites and causes structural 
changes in the PTC, while macrolides like erythromycin hinder protein biosynthesis by 
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stopping the growing peptide chain from passing through the ribosomal exit tunnel 
(Hermann, 2005).   
The cell wall is the first line of defence for the bacterium and very critical for its 
survival. Inhibiting bacterial cell wall synthesis can have a variety of effects on the 
bacterial cell such as changes to cell shape and size, induction of a cellular stress response 
and cell lysis. Penicillin, which belongs to the β-lactam class of antibiotics, targets the 
transpeptidase known as penicillin-binding protein (PBP), which catalyses the peptide 
bond formation that crosslinks the peptidoglycan blocks. Cell wall synthesis can also be 
inhibited through blocking both transglycosidase and transpeptidase activity, a strategy 
that is utilized by vancomycin via binding to the D-Ala-D-Ala C- terminus of the 
pentapeptide. This blocks the addition of late precursors by transglycosylation to the 
nascent peptidoglycan chain, and consequently results in reduction of the cellular 
mechanical strength and an incomplete cell wall (Kohanski et al., 2010). Fosfomycin 
works by inhibiting MurA, the enzyme involved in catalysing the first step of the 
peptidoglycan synthesis, and Daptomycin induces calcium–dependent membrane 
depolarisation, which leads to disruption of the bacterial cellular membrane (Bush, 2012). 
Exploiting bacterial Folic acid biosynthesis as an antibiotic target has been recognised for 
years. Sulfonamides were the first folic acid pathway inhibitors introduced as early as the 
1930s. They work as alternative substrates for dihydropteroate synthase, one of the 
pathway’s enzymes, leading to depletion of the folate pool and therefore inhibition of 
bacterial growth by preventing DNA replication. Dihydrofolate reductase (DHFR) is the 
final enzyme in the pathway, and it is targeted by the diaminopyrimidine (Bermingham 
and Derrick, 2002), (Figure 1.1). 
  
6 
 
 
 
 
Figure 1.1 Principle targets of antibiotics. Drug target interactions can take different 
forms depending on which bacterial function is affected. Quinolones interfere with DNA 
supercoiling which leads to the formation of double stranded DNA breaks and eventually 
cell death.  Tetracyclines inhibit protein synthesis by blocking the tRNA binding site. 
Chloramphenicol also interferes with protein synthesis but via different route - it interacts 
with the peptidyl-transferase centre in ribosomal 50S subunit and prevents binding to the 
A-site tRNA with the attachment of mRNA to the 50s ribosome, which consequently 
inhibits protein synthesis. β-lactams target cell wall synthesis binding to PBPs and 
decreasing peptidoglycan synthesis. 
 
As antibiotic resistance is a growing threat, other antimicrobial targets are being 
explored in a bid to keep up with the evolutionary process of the bacterial resistance. 
Cell Wall synthesis 
Vancomycin 
Penicillin 
Cephalosporin 
D-cycloserine 
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Acyldepsipeptidolactones are among the currently examined natural products with a novel 
antibacterial mode of action. With the acyldepsipeptide (ADEP) being the main 
component, this group of antibiotics work by disrupting the highly regulated protease 
activity of the ClpPs resulting in a fast degradation of the essential cellular proteins and 
eventually cell death (Clardy et al., 2006). Fatty acid biosynthesis is also becoming an 
interesting target for pharmaceutical companies. For example, Platensimycin was reported 
to be potentially active against Staphylococcus aureus by limiting the activity rate of FabF 
and was tested in mouse models infected with S.aureus, resulting in 104 to 105 fold 
reductions in bacterial counts (Clardy et al., 2006, Wang et al., 2006). However, despite 
the in vivo activity established in the mouse model, Platensimycin is not ready for clinical 
use due to its poor pharmacokinetic profile (Allahverdiyev et al., 2013). 
1.1.2 Antibiotic resistance  
 
The introduction of antibiotics is recognised as one of the most important medical 
achievements of the 20th century, and in the early days many believed that this would 
provide a permanent solution. By contrast, there is now great concern that without drastic 
action we may no longer be able to control many common infections due to the causative 
bacteria becoming resistant to all available antibiotics. However, while antibiotic 
resistance has been exacerbated by human use and misuse of antibiotics, most antibiotic 
biosynthesis pathways evolved millions of years ago suggesting that antibiotic resistance 
predates the clinical use of antibiotics.  Therefore, while the introduction of antibiotics 
may be a factor, it is  not the only cause for the acquisition of modern resistance genes 
(Wright and Poinar, 2012).  
To study the evolution of resistance genes, DNA samples were collected from Late 
Pleistocene permafrost sediments. The samples were found to include genes for: the 
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ribosomal protection protein TetM, which confers tetracycline resistance, VanX a part of 
the Vancomycin resistance pathway, and a β-lactamase belonging to the TEM group of the 
β -lactamases.  Several tetM-related genes were identified, most of them are very similar to 
the Actinomycetes ribosomal protection protein (Costa et al., 2011).  Phylogenetic analysis 
of Vancomycin resistance genes confirmed that many of the ancient VanHAX operon 
sequences are statistically similar to the modern Vancomycin resistance genes. To confirm 
that the 30,000 years old Vancomycin resistance genes are actually related to the modern 
proteins, researchers used crystallography to determine the 3D structure of VanA (Brown 
and Balkwill, 2009, Costa et al., 2011). Results showed that the quaternary and tertiary 
structure of VanA contained the D-Ala-D-X ligase fold similar to the currently existing 
enzymes, including VanA from Vancomycin resistant Enterococcus faecium.  There have 
also been reports of finding antibiotic resistance among bacteria in extreme environments 
like deep terrestrial subsurface and deep oceans.  Since one of the critical factors in this 
kind of research is ensuring the absence of anthropogenic sources of antibiotics, studies 
were also conducted in isolated places such as Lechuguilla Cave in Mexico, which has 
been isolated for more than 4 million years and provides the perfect ecosystem to study the 
evolution of resistance genes. In this study 93 bacterial strains were tested for 
antimicrobial susceptibility, of the strains 70% were resistant to 3-4 different antibiotics, 
while 3 strains were resistant to 14 antibiotics (Bhullar et al., 2012). All these studies 
support the hypothesis that antibiotic resistance is an ancient and natural phenomenon and 
it is not a mere result of antibiotic introduction.  
Bacterial resistance to antimicrobial agents can be manifested in several ways. The 
first way is that it can be innate or intrinsic, where species or genera of bacteria are 
inherently resistant to a particular class of antibiotics. For example, Pseudomonas 
aeruginosa exhibits low antibiotic susceptibility due to reduced permeability of its outer 
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membrane, in addition to the intrinsic presence of β-lactamase in the periplasm which 
inactivates β-lactams (Cox and Wright, 2013).  Another element of intrinsic resistance is 
efflux pumps. In E. coli the AcrAB-TolC RND efflux system plays an important role in its 
resistance to a broad range of antibiotics such as tetracyclines, fluoroquinolones, ß-lactams 
and the macrolides.  Bacteria can also acquire genes for a metabolic pathway that produces 
altered bacterial cell walls that do not contain the binding site for the antibiotic (Tenover, 
2006).  Mutations can also cause the bacterium to develop resistance by altering the target 
protein to which the antimicrobial agent binds to, as in the case of penicillin – binding 
protein (e.g., change in penicillin-binding protein 2b in pneumococci), through production 
of enzymes that inactivate the antibiotic such as the erythromycin ribosomal methylase in 
staphylococci, or by up-regulating pumps that expel the antibiotic from the bacterial cell 
(e.g., efflux of fluoroquinolones in S.aureus) (Livermore, 2003).While the previous means 
of acquiring resistance were through chromosomal mutations and selection, bacteria can 
also develop resistance through horizontal gene transfer, which is essentially exchanging 
with other bacteria the genetic elements that encode resistance (Tenover, 2006) (Figure 
1.2).  This can occur through conjugation, during which Gram negative bacteria (and some 
Gram positive bacteria) transfer a resistance plasmid via pili and Gram positive bacteria 
exchange DNA by producing pheromones that facilitate the clumping of the donor and 
recipient bacterium (Tenover, 2006).   In transduction, the resistance plasmid or 
transposable element is transferred from one bacterium to another by a phage; while 
transformation allows the bacteria to acquire resistance by uptake and incorporation of 
naked DNA into the bacterial genome (Davies and Davies, 2010).  
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Figure 1.2 Mechanisms of antibiotic resistance. Bacteria can avoid antibiotic effects by: 
altering the antibiotic’s target through mutation, the presence of efflux pumps, production 
of inactivating enzymes that interfere with the function of the antimicrobial agent.  
 
1.1.3 Implication of antibiotic resistance  
Antibiotics could be considered one of the greatest discoveries of the 20th century, 
however there is a threat of transition to a post antibiotic era, where increasing levels of 
antibiotic resistance may make a simple bacterial infection life threatening. When 
penicillin became available in 1940, almost all Staphylococcus aureus strains were 
susceptible to its antimicrobial effect, but shortly thereafter, S. aureus became capable of 
resisting penicillin by destroying it with β-lactamases (Neu, 1992). Today 95% of S. 
aureus worldwide is resistant to penicillin.  Methicillin was introduced in 1959, but it was 
not long before resistance cases started to appear in several countries, The United 
Kingdom, Poland and Denmark at first and then it spread to the United States by the early 
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1980s. Methicillin Resistant S. aureus (MRSA) was resistant to all the main classes of 
antibiotics that were in circulation at that time, β-lactams, erythromycin, fusidic acid, 
streptomycin and tetracycline (Howden et al., 2010).  
Now that MRSA has become a source of major concern, clinicians turned to 
vancomycin which was released in 1958 and was the only agent that is used successfully to 
treat MRSA (Howden et al., 2010). Unsurprisingly, the increased use of vancomycin has 
not only selected resistance against vancomycin in MRSA but also in Enterococci faecium, 
61% of which are now resistant to vancomycin. As MRSA continued to pose a serious 
threat, the scientific community was again under pressure to come up with a new molecule 
in order to tackle the resistance problem. In the mid-1980s fluoroquinilones provided a 
solution, and initially they were able to inhibit MRSA growth at <2µg/ml (Howden et al., 
2010). Today MRSA resistance to ciprofloxacin, a synthetic version of nalidixic acid, is 
greater than 80% and less than 20% of MRSA isolates are actually eradicated by the 
currently available antimicrobial agents (Neu, 1992, Fair and Tor, 2014).   
Mupirocin was first introduced into clinical practice in the UK in 1985. It showed 
high efficacy against MRSA by targeting bacterial protein synthesis. However, within a 
short period of its introduction high levels of mupirocin resistance in S. aureus started to 
appear, especially in patients who had received long-term mupirocin treatment (Hardy et 
al., 2004). All the previously mentioned examples demonstrate the capability of bacteria to 
quickly develop resistance against virtually any antibiotic class, which makes it critical to 
find new antimicrobial classes to combat bacterial resistance. Despite this urgent need, 
there has been a lack of novel antimicrobial agents discovered. The number of newly 
approved antibiotics from 1998 – 2002 was 56% lower than in the period from 1983- 1987 
(Figure 1.3). Since 2002, eight antibiotics have been approved, only two of which had a 
new mode of action: anidulafungin and linezolid (Spellberg et al., 2004). Another issue 
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with the development of new antibiotics is the lack of diversity. Approximately half of all 
antibiotics target the cell wall and although studies have recently started to identify novel 
molecular targets, their activity is usually insufficient to be carried into production stage 
without further modification (Projan, 2003; Fair and Tor, 2014).   
 
Figure 1.3 Antibiotics introduced into clinical practice.  Antibiotics above the timeline 
indicate the year they were introduced in, while the antibiotics below the timeline show the 
year resistance was observed reproduced from (Clatworthy et al., 2007) 
 
Another impact of the increase of antimicrobial resistance is the rise of 
“superbugs”. These microbes not only have reduced therapeutic options available due to 
their multiple drug resistance (MDR), but they also have an economic impact as the period 
of hospital care is extended (Davies and Davies, 2010). In 2006, the term extensively drug 
resistant TB (XDR TB) was used to define TB strains with resistance to isoniazid and 
rifampicin, in addition to all the fluoroquinolones and at least one of the injectable 
tuberculosis drugs (Amaral et al., 2009). In 2007, Italy was the first country to report total 
drug resistant TB (TDR-TB), followed by 15 TDR TB cases in Iran in 2009 (Udwadia, 
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2012). According to the WHO 2 million people will develop MDR TB by 2015, and in 
most of the cases 50% of these infections will be XDR TB (Mishra et al., 2014).  
Today 60% of hospital acquired infections are caused by MRSA (CDC, 2015), 
accounting for an estimated one million extra days of hospitalization in the EU alone, 
costing approximately $570 million. The infections caused by community acquired MRSA 
has reached the endemic stage in many European countries, US and parts of Asia, in 
addition to being the most frequent cause for emergency room visits in the United States 
(Chatterjee and Otto, 2013). 
Enterococcus resistance is endemic in North America, while it is on the rise in 
Europe. Enterococcus species have been considered the second most common cause of 
wound and urinary tract infections, with 12% of the nosocomial infections in the USA 
being caused by E. faecalis (Arias and Murray, 2012). Recent studies showed that 60% of 
E.  faecium is resistant to vancomycin, which are currently treated with either linezolid, to 
which resistance does occur but rarely, or daptomycin that until recently had a promising 
potential in circumventing vancomycin resistant E. faecium (VRE). However, clinical 
isolates of E. faecium showed that resistance can still arise by spontaneous mutations in the 
gene liaF and a second gene responsible for membrane phospholipid metabolism. This 
observation was also confirmed by comparative analysis which revealed that daptomycin 
is less effective in depolarizing the cell membrane in the resistant strains due to the 
alterations in the cell wall ultrastructure and cell membrane (Arias and Murray, 2012). 
MDR P. aeruginosa is also increasing worldwide with limited treatment options, as β-
lactams, fluoroquinolones and aminoglycosides are no longer effective. Colistin was found 
to be active against P. aeruginosa with new reports suggesting that using it in combination 
with rifampin proved active in vitro. However, patients need to monitored to check for any 
toxicities associated with this agent (Obritsch et al., 2005).  
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Another concern is the NDM-1 (New Delhi metallo – beta lactamase 1), an 
enzyme which encodes resistance to β-lactams antibiotics, generally found on a plasmid 
that harbours many other resistance genes, which makes it resistant to a wide range of 
antimicrobial agents with the exception of colistin. Worryingly, it is found on a 
transmissible genetic element which means the resistance can easily disseminate to other 
bacterial strains.  Given previous spread of resistant strains, we can already predict that 
NDM-1 is close to being a serious health threat and can turn any strain that contains it into 
a super bug (Moellering, 2010).  
Despite the increasing resistance problems, international efforts to control the 
crisis have not been particularly successful, because of a lack of coordination and a little 
novel antibiotic development due to the lack of investment by pharmaceutical companies 
(Carlet et al., 2012). Without significant big pharmaceutical company contribution, most 
of the actual research in this regard is actually carried out in academic centres and small 
biotechnology companies.  
As of September 2014, seven new antibiotics reached phase three, in addition two 
compounds are currently being reviewed by the FDA, which have the potential to be used 
against Gram negative bacilli (Hay et al., 2014). The fact that 75% of currently used 
antibiotic scaffolds are based on natural products tells us a great deal about the potential of 
complex environments to yield organisms with antimicrobial activities (Taylor, 2013).  
Enacyloxins were originally identified in Frateuria sp in 1982 (Watanabe et al., 1982), but 
they were recently back in the spot light when it was discovered that they can be also 
produced by Burkholderia ambifaria. The importance of this finding is not limited to the 
new producer, but also to the newly elucidated biosynthetic pathway, a hybrid of non-
ribosomal peptide synthase and polyketide synthase. This concept of hybrid biosynthetic 
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pathways could open the door for more modifications and pathway engineering in order to 
produce a novel, more effective version of enacyloxins (Pidot et al., 2014). 
Janthinocin A, B and C have been in use since the 1990s to treat infections by 
Gram positive bacteria including MRSA. Researchers are now trying to isolate an 
antifungal compound from the producer organism Janthinobacterium lividum, a known 
cause for soft rot. J. lividum is thought to produce the active antifungal compound only 
when in contact with the host plant. This research certainly highlights the importance of 
extending our antibiotic hunt to even virulent organisms and benefit from their toxins in 
human therapeutics (Pidot et al., 2014).  
Predatory bacteria are also becoming an interesting alternative to antibiotics.  
Organisms like Bdellovibrio bacteriovorus are obligate predators of Gram–negative 
bacteria for energy and nutrients.  The Bdellovibrio genome contains several hydrolases 
essential for prey digestion and more importantly for attacking bacterial biofilms (Allen et 
al., 2014). Screening of previously approved drugs can also be a useful approach to 
appease this urgent need for new antibiotics, as their known pharmacology and toxicology 
profiles will reduce the cost of developing an entirely new drug by almost 40%. This was 
demonstrated by the Wright group, where 30,000 compounds were screened from the 
Canadian compounds collection. Four compounds were identified and showed synergism 
with novobiocin against E. coli.  Furthermore, these four compounds were found to affect 
the cell shape and bacterial membrane permeability, which provides a physical base for 
this synergy (Worthington and Melander, 2013). CRISPR (clustered regularly interspaced 
short palindromic repeats) have recently emerged as tools with a strong potential to target 
and destroy bacterial pathogens in a way that compensate for the drawbacks of most of the 
currently known antibiotics. CRISPR are used to create sequence–specific antimicrobials 
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that can be aimed exclusively towards resistant bacteria, unlike the traditional antibiotics 
which kill off both pathogenic and beneficial bacteria (Kahrstrom, 2014). 
Many international organizations have joined forces to develop a strategy for 
combating antibiotic resistance. The European commission released a list of key actions to 
successfully fight antibiotic resistance. WHO issued a series of recommendations in 
2001(WHO global strategy for containment of antimicrobial resistance), which was a 
culmination of expert workshops, consensus meetings and consultative groups to evaluate 
the situation (WHO, 2001). The American government put together a national strategy to 
control antibiotic resistance in collaboration with partners in healthcare public health, 
academic, industrial and federal research. In 2009, the EU-US summit agreed on 
establishing TATFAR (transatlantic task force on urgent antimicrobial resistance) with the 
objectives of promoting appropriate use of antibiotics, and increasing the US and the EU’s 
mutual understanding relevant to the antibiotic problem, which includes exchange of 
information, coordination and cooperation (Antibiotic Action, 2011). Some developing 
countries are also contributing to the worldwide effort, through GARP (Global Antibiotic 
Resistance Partnership) which currently works in four countries: India, South Africa, 
Kenya and Vietnam intially. These policies and guidelines collectively led to a number of 
recommendations which can be summarized below:  
 Optimizing prescribing practice and promoting appropriate use of antibiotics 
 Improving infection prevention methods 
 Encouraging and reinforcing research to develop new and effective antibiotics 
 Providing better access to surveillance data 
 Strengthening international collaboration 
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 Developing quick tests to be used in health care centres for distinguishing between 
a viral and a bacterial infection, and consequently the need for using antibiotics 
(CDC, 2014; Leung et al., 2011; Gottlieb and Nimmo, 2011)    
 
1.2 Polyketides 
Polyketides are an important class of natural products, with both diverse 
structures (Figure 1.4) and clinical functions, including antibiotics like erythromycin and 
tetracycline, anticancer drugs and immune-suppressants (Abe, Simpson, 1987, Zheng and 
Keatinge-Clay, 2012). Polyketides are synthesized by bacteria, fungi and some plants. 
 
 
 
Figure 1.4 Examples of different polyketides. 
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Polyketides are produced in vivo by polyketide synthase enzymes (PKS). Three 
types of PKS have been identified so far, type I, type II that contain a single set of 
iteratively acting enzymes and type III. A characteristic feature of type I PKSs is the 
presence of multiple active sites within each polypeptide. In the iterative type I PKS a 
single multienzyme is used repeatedly for multiple condensation reactions. Whereas, the 
modular type I PKS incorporates a set of enzymatic domains for each catalytic cycle. They 
contain multifunctional polypeptide units grouped into modules, each module consists of 
at least three domains β-ketosynthase (KS), acyltransferase (AT) and acyl carrier protein 
(ACP), with the exception of trans-AT systems. Some modules also contain β-keto-
processing domains, β-ketoreductase (KR), dehydratase (DH) and enoylreductase (ER). A 
thioesterase (TE) is often found at the end of the last module and it is responsible for 
releasing the product from the enzyme. Examples of polyketides produced by this type of 
synthase are erythromycin, rapamycin and avermectin (Hopwood, 1997, Hopwood and 
Sherman, 1990). Type II PKSs are multi-enzyme systems with each catalytic activity 
located on a separate protein subunit (McDaniel et al., 1995). Type III PKS systems differ 
from the previous two by having a single protein system that does not contain a domain or 
modular structure. Also type III PKS does not involve a carrier protein but instead it uses 
acyl-CoA as a substrate  (Hertweck, 2009). 
Polyketides have attracted much interest recently, especially in the metabolic 
engineering field due to their flexibility in substrate selectivity which results in the 
difference of reduction levels of the β-keto groups, the length of the polyketide chain and 
the degree of post-PKS modification, which all together allow the formation of a diverse 
product spectrum and make PKSs a very promising area for drug discovery (Piel, 2010) 
(Gao et al., 2010). 
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1.2.1 Fatty acids 
Fatty acid biosynthesis is closely related to polyketide synthesis and is an 
important process in all living organisms.  Many of the vital functions in bacteria depend 
on fatty acid synthase (FAS) pathways, including membrane biosynthesis and quorum 
sensing. As shown in (Figure 1.5), the fatty acid synthesis system can be divided into two 
groups, FAS type I and FAS type II. Whilst type II express all the proteins as individual 
polypetides from separate genes, FAS type I expresses large multi-enzyme complexes that 
carry all the necessary proteins for fatty acid synthesis on one or two polypetide chains. 
Mammalian (FAS II) consists of two identical polypeptide chains, each containing all the 
required domains for the biosynthesis process, including: β-ketoacyl synthase, malonyl 
acetyl transferase, dehydratase, enoyl reductase, β-ketoacyl reductase, ACP and 
thioesterase. The first step in the biosynthesis process is a condensation reaction between a 
malonyl group derived from malonyl-CoA, and an acetyl group from acetyl-CoA. This 
process results in the formation of a β-ketoacyl derivative which is then reduced in three 
steps: β-ketoacyl reduction, β-ketohydroxyacyl dehydration and finally enoyl reduction. 
The resulting saturated acyl derivative acts as a primer for further elongation and reduction 
cycles to yield a palmitoyl derivative, which is then hydrolysed by thioesterase and 
palmitate is released (Menendez et al., 2009). 
In E. coli fatty acid biosynthesis falls into the FAS type II category. The growing 
chain is dependent on two coenzymes, coenzyme A and an ACP, which are responsible for 
supplying precursors for the condensation reaction (Campbell and Cronan, 2001, 
Magnuson et al., 1993). The starter unit (acyl) is attached to the cysteine thiol of the 
ketosynthase (KS), while the extender unit (malonyl) is attached to the phosphopantetheine 
thiol residue of the acyl carrier protein, ACP.  The chain extends into a β-ketoester, which 
is reduced by ketoreductase (KR), dehydrated by a dehydratase (DH) and then a final 
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reduction by the enoyl reductase (ER). The extended chain is then transferred back to the 
KS to go through another cycle of successive steps, which is repeated until the chain 
reaches its designated length. The full length chain is finally passed to the thioesterase 
(TE), where it is released as a free acid or an acyl ester (Staunton and Weissman, 2001). 
 
 
 
Figure 1.5. Fatty acid biosynthesis.  Contrary to polyketide biosynthesis, the resulting β-
ketoacyl is always completely reduced. MAT, malonyl-CoA-ACP transferase; AT, 
acyltransferase; ACP, acyl carrier protein; KS, ketosynthase; KR, Ketoreductase; DH, 
Dehydratase; ER, enoyl reductase. Reproduced from Staunton and Weissman (2001). 
 
1.2.2 Type I polyketide synthases 
Type I PKSs are large multifunctional enzymes usually > 300 KDa, arranged into 
modules each of which contain a set of domains responsible for catalysing one 
condensation reaction (Dittmann et al., 2001). A type I PKS module needs at least three 
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enzymes to be functional: an acyl transferase (AT), an acyl carrier protein (ACP) and a 
ketosynthase (KS) (Cheng et al., 2009). Modules may also contain ketoreductase (KR), 
dehydratase (DH) or enoylreductase (ER), which are optional domains that give 
polyketides their structural diversity (Piel, 2010). Most of the types I PKSs have a 
thioesterase (TE) domain which is responsible for “off-loading” the resulting polyketide. 
Modular PKSs use every catalytic site once during a cycle, and usually in such systems the 
number of modules is an indication of the number of elongation and reduction cycles 
which makes it easy to predict the resulting polyketide structure (He and Hertweck, 2005). 
However, some polyketides are an exception to this co-linearity like the aureothin 
biosynthesis pathway where only four modules are required to catalyze five rounds of 
Claisen condensation (Busch and Hertweck, 2009).  Polyketide biosynthetic pathways that 
breach this co-linearity include many other compounds, like borrelidin gene cluster which 
uses a single elongation module three times, or lankacidin in which iterative use of some 
of the modules is observed (August et al., 1998, He and Hertweck, 2005). Iterative 
pathways among PKSs are more common than we think, but the basis on which this 
iterative or non-iterative behaviour occurs is still a mystery to be solved.  
1.2.2.1 Erythromycin biosynthesis pathway 
 
The search for the erythromycin gene cluster progressed after Thompson et al., 
(1982) discovered a clone derived from Saccharopolyspora erythraea that conferred 
erythromycin resistance to Streptomyces lividans implying that the clone contains ermE 
(the erythromycin resistance gene). This finding was then followed by (Tuan et al., 1990) 
who paved the way to identify the erythromycin gene cluster by sequencing upstream and 
downstream of ermE (Rawlings, 2001). Three genes, eryAI, eryAII and eryAIII, are large 
opening reading frames in the erythromycin biosynthetic pathway coding for three large 
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multifunctional proteins DEBS1, DEBS2 and DEBS3 respectively (Figure 1.6) (Staunton 
and Wilkinson, 1997; Weissman and Leadlay, 2005).  Similar to other type I PKS systems, 
each module contains the essential three domains: ketosynthase (KS) that catalyses the 
decarboxylative condensation of the methylmalony–ACP building block with the starter 
unit or polyketide chain provided by the previous PKS module, acyl transferase (AT) that 
is responsible for loading the extender unit onto the phosphopantetheine arm of the ACP 
domain, and acyl carrier protein (ACP) that holds the growing polyketide chain and 
delivers the resulting polyketide chain to the KS domain in the next module (Cane, 2010). 
Optional domains are also present in the pathway and they perform reductive modification 
to the growing chain before the next round of chain elongation. 
 
Figure 1.6 Erythromycin biosynthesis pathway.  DEBS is the best studied PKS, it 
catalyses the key steps to erythromycin biosynthesis. The biosynthetic pathway involves 
six Claisen condensations and several reduction steps in order to release erythromycin A 
through a terminal esterase. Domains are acyltransferase (AT), acyl carrier protein (ACP), 
ketosynthase (KS), ketoreductase (KR), dehydratase (DH), enoyl reductase (ER), and 
thioesterase (TE) (Staunton and Wilkinson, 1997; Weissman and Leadlay, 2005). 
 
The starter unit (propionate) is loaded by the AT and ACP which are linked 
together. Although in vivo the loading domain is able to accept only acetate or propionate, 
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in vitro studies showed that a variety of starter units can be accepted like butanoate and 2-
methylpropanoate. Apart from module 3, all the other modules have reductive domains. 
Modules 1, 2, 5 and 6 all have a KR which catalyses reduction of keto group to a hydroxyl 
group, while module 4 contains all the reductive domains (KR, DH and ER) to produce a 
fully reduced alkane (Staunton and Weissman, 2001). The fully formed compound is 
released by the TE domain which catalyses the lactonization of the complete polyketide 
chain. 
1.2.3 Type II polyketide synthases 
Type II PKSs, found in bacteria and plants, assemble an iterative multienzyme 
complex by encoding distinct proteins (Lal et al., 2000; Moore and Hopke, 2001; Chopra 
et al., 2008). KSα, KSβ (chain length factor) and ACP are the minimal set of modules 
needed to produce a basic polyketide backbone in the type II PKS. However, additional 
enzymes are required to fold and cyclise the polyketide chain into a polycyclic structure; 
these enzymes include cyclases and their equivalent aromatases (Staunton and Weissman, 
2001). Additional tailoring of the polyketide chain is performed by oxygenase, glycosyl 
and methyl transferases. The chain assembly starts with the KSα and KSβ (CLF) forming a 
heterodimer (Hertweck et al., 2007). The length of the resulting polyketide chain is 
determined by KSβ (CLF). According to Khosla and co-workers, the region responsible for 
the chain length is located at the interface of the dimer with certain residues in that region 
acting as gatekeepers in the polyketide tunnel, and so reducing the size of these residues 
elongates the channel, allowing two more elongation cycles (Seow et al., 1997). Unlike the 
tight association between KSα and KSβ (CLF), the interaction between KSα and ACP is 
specific but weak enough to give multiple exchanges of KSα-ACP during the biosynthetic 
process. Following the formation of each successive C-C bond, the growing chain is 
transferred back from the ACP to the KS before the protein detaches (Das and Khosla, 
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2009). Further enzymes are needed to convert the basic polyketide chain into a polycyclic 
aromatic product. These enzymes can be categorized as auxiliary PKS enzymes which 
recognize ACP bound substrates and tailoring enzymes.  Once the chain reaches its full 
length, the ACP dissociates from the polyketide chain attached to it, by hydrolysis or 
cyclisation or by the activity of auxiliary PKS functions like KR, ARO/CYC. Tailoring 
enzymes then transform the polyketide chain into a fully decorated natural product as in 
the case of actinorhodin (Figure 1.7) (Das and Khosla, 2009, Hertweck et al., 2007). 
 
Figure 1.7  Biosynthesis by a PKSII system.  KS and CLF domains have the function of 
catalysing chain initiation and elongation with malonyl as a building block.  The resulting 
poly-β-keto intermediate is then modified by tailoring enzymes such as KR, CYC and 
ARO into actinorhodin. Reproduced from (Staunton and Weissman, 2001). 
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1.2.4 Type III polyketide synthases 
Type III PKSs are homodimers, and the active site in each monomer catalyses 
iteratively the priming, extension and cyclization reactions to produce the final polyketide 
molecule. Until recently type III PKSs were thought to be specific to plants, and it was 
only in 1999 when the first bacterial type III PKS RppA was discovered amongst other 
putative compounds (Hashimoto et al., 2014, Agnes and Scott, 2007). To date five groups 
of bacterial type III PKSs are recognised based on the structure of the resulting molecule. 
RppA from Streptomyces griseus, is responsible for catalyzing production of 1,3,6,8-
tetrahydroxynaphthalene. The others are: Ph1D from Pseudomonas fluorescens which is 
known for its broad substrate specificity, DpgA from Amycolatopsis orientalis which only 
uses malonyl-CoA as a substrate to synthesise 3,5-dihydroxyphenylacetyl-CoA, ArsB 
from Azotobacter vinelandii, and SrsA from S. griseus which catalyze the formation of 
alkylresorcinols (Yu et al., 2012). The interesting feature about the latter group of PKS 
type III systems is that the ars operon contains two genes which encode a putative type I 
FAS: ArsA and ArsD. These enzymes synthesize a fatty acid chain that is directly 
transferred onto the active site cysteine of ArsB, thus enabling ArsB to utilize the fatty 
acid from acyl-ArcAs as the starter substrate, followed by three rounds of condensation 
with the extender unit malonyl–CoA, to finally produce alkylresorcinols. Two different 
extender units, methylmalonyl-CoA and malonyl-CoA, are used by SrsA to eventually 
synthesise alkylresorcinols in a similar manner to ArsB. The final group of type III PKSs 
includes alkylpyrone synthases like ArsC from A. vinelandii and germicidin synthase Gcs 
from S. coelicolor. They are unusual in that they utilize unnatural acyl-CoAs and ACP 
linked acyl-CoAs as starter units (Chemler et al., 2012, Nakano et al., 2009, Yu et al., 
2012). Type III PKSs are also present in fungi, with some promise in terms of discovering 
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new biosynthetic pathways, and the creation of novel unnatural/natural products 
(Hashimoto et al., 2014). 
1.3 Mupirocin  
Pseudomonas is a diverse genus of Gamma proteobacteria which can be found in 
wide range of environments including soil, water, plant surfaces and animals. They are 
well known for their capacity to utilize a variety of organic compounds as energy sources, 
their medical and agricultural importance, their resistance to many antimicrobial 
compounds, and also for their remarkable metabolic capacity. Pseudomonas spp. produce 
a large array of natural products that have a wide range of biological activities. Studying 
the structure and the biosynthetic pathway of these metabolites led to the discovery of 
many novel antimicrobial compounds and new biosynthetic mechanisms (Gross and 
Loper, 2009). Of particular interest is Pseudomonas fluorescens, more than 100 years ago 
Baader and Garre (1887) first noticed its antimicrobial activity when grown on gelatine. 
This antibacterial compound was able to inhibit the growth of Staphylococcus aureus, 
Salmonella typhi, and Bacteroides friedlanderi in addition to yeasts (Lewis, 1929, Pappa, 
1990). An interesting observation was made by I. M. Lewis when he noticed that spore 
forming bacteria and micrococci were sensitive to the substance produced by P. 
fluorescens, in contrast to Gram negative and Gram positive bacilli which showed some 
resistance. In the 1960s Fuller and co-workers were able to make some progress in 
optimizing the growth conditions and culture media appropriate for the P. fluorescens 
growth. This yielded sufficient amounts of the antibiotic for further studies (Pappa, 1990, 
Fuller et al., 1971). Later on Chain and co-workers discovered that the antimicrobial 
activity exhibited by P. fluorescens is all due to pseudomonic acid, which was further 
characterized and divided into four groups of metabolites collectively named mupirocin. 
The four types are pseudomonic acid A, B, C and D, where pseudomonic acid A is the 
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major metabolite which accounts for 90% of mupirocin (Figure 1.8) (Sutherland et al., 
1985, Chain and Mellows, 1977). 
 
Figure 1.8 Mupirocin chemical structures. Mupirocin is a mixture of pseudomonic acids: 
pseudomonic acid A (90%), pseudomonic acid B (8%) has an extra hydroxyl group at C8, 
pseudomonic acid C (<2%) has a double bond in the position C10 to C11, and 
pseudomonoc acid D (<2%) contains an unsaturated fatty acid chain at C4’ and C5’. 
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1.3.1 The mupirocin biosynthetic cluster 
The mupirocin biosynthesis cluster is approximately 74 kb in size and encodes 35 
ORFs. The cluster contains six multifunctional genes (mmpA,B,C,D,E and F) and various 
genes with individual functions, two of which are located in the first 40.5 kb of the cluster 
(mupA and mupB) (Figure 1.9). Some of the individual genes like mupB, mupD, mupG and 
mupS show similarity to type II PKSs, which suggests that, the mup cluster is a 
combination of both Type I and Type II PKSs, (Figure 1.9) (El-Sayed et al., 2003). The 
first four elongation modules for the monic acid backbone are encoded by mmpD, and the 
last two encoded by mmpA. These type I PKSs consist of KS, ACP, KR, DH and MT 
domains. The only two AT domains in the pathway are encoded by mmpC, which also 
encodes a putative ER. A type I iterative PKS with KS, KR, DH and triple ACP domains is 
encoded by mmpB, and is thought responsible for synthesis of 9HN moiety. The mmpB 
gene is proposed to encode the only TE in the system, which implies that it facilitates the 
final steps of the pathway and the release of the final product (Thomas et al., 2010). 
Despite its similarity to type I PKSs, the mup cluster possesses some features that 
do not follow the typical modular pattern. As is the case in many PKS systems, loading 
modules are specifically designed to accept the starter unit in order to initiate the metabolic 
process. However, the mup cluster lacks an obvious loading module. So far the proposed 
theory on how such systems work includes a malonate residue, which is loaded to the first 
KS domain and then decarboxylated to provide acetate as a starter unit (El-Sayed et al., 
2003, Thomas et al., 2010). AT domains in the mup cluster belong to a growing family of 
PKSs called the trans AT PKSs. This terminology refers to the AT domains are encoded 
by a separate gene in the pathway, as opposed to cis AT pathways, where the AT domain 
is present in each and every module. Despite being common amongst other trans AT 
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PKSs, the reason behind the unusual domain architecture seen in both MmpA and MmpB, 
which contain a tandem doublet and triplet ACPs respectively is still not fully understood. 
However, the fact that they are more closely related to each other than any other ACP in 
the cluster, suggests that they might be a result of a gene duplication event (Gurney and 
Thomas, 2011, Rahman et al., 2005) 
 
 
Figure 1.9 Organisation of mupirocin biosynthesis cluster. The mup cluster is localised 
to a 74 kb region of the P. fluorescens chromosome. Genes are shown as blue arrows; 
domains are coloured as indicated (El-Sayed et al., 2003, Thomas et al., 2010). 
  
 
 
Table 1.1 Deduced functions of mup genes (El-Sayed et al., 2003, Thomas et al., 2010). 
ORF Deduced Function 
 
mupA          Reduced flavin mononucleotide (FMNH2) oxygenase 
mmpA         Polyketide synthase (ketosynthase, acyl carrier protein and ketoreductase) 
mupB          3-Oxo-acyl carrier protein synthase 
mmpB         Polyketide synthase (ketosynthase, dehydratase, ketoreductase, acyl carrier protein 
and thioesterase) 
mmpC         Acyltransferase and enoyl reductase 
mmpD         Polyketide synthase (ketosynthase, dehydratase, ketoreductase, methyltransferase 
and acyl carrier protein) 
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mupC          Dienoyl CoA reductase 
macpA        Acyl carrier protein 
mupD          3-Oxo-acyl carrier protein reductase 
mupE          Enoyl reductase 
macpB        Acyl carrier protein 
mupF          Ketoreductase 
macpC       Acyl carrier protein 
mupG         3-Oxo-acyl carrier protein synthase 
mupH      β-hydroxyl-β-methyl glutarate CoA synthase 
mupJ         Enoyl CoA hydratase 
mupK         Enoyl CoA hydratase 
mmpE        Polyketide synthase (ketosynthase and hydroxylase) 
mupL         Hydrolase 
mupM        Isoleucyl-tRNA synthetase 
mupN        Phosphopantetheinyl transferase 
mupO       Cytochrome P450 
mupP        Unknown 
mupQ       Acyl CoA synthase 
mupS       3-Oxo-acyl carrier protein reductase 
macpD     Acyl carrier protein 
mmpF      Polyketide synthase (ketosynthase) 
macpE     Acyl carrier protein 
mupT       Ferrodoxin dioxygenase 
mupU      Acyl CoA synthase 
mupV     Oxidoreductase 
mupW    Dioxygenase 
mupR     Transcriptional activator 
mupX     Amidase 
mupI     N-Acyl homoserine lactone synthase 
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1.3.2 Mupirocin biosynthesis 
The biosynthetic pathway starts with the activation of the substrates and the condensation 
of the carboxylic acid starter unit which is catalysed by the KS (Gurney and Thomas, 
2011). The extender unit is then transferred on to the phosphopantetheine arm of the ACP, 
and at this stage the condensation reaction takes place between the starter and the extender 
unit, joining them together by the action of KS. The resulting product is either left 
unreduced, or is partially or completely reduced depending on the presence of optional 
reductive enzymes in the pathway: ketoreductase KR, dehydratase DH and enoyl reductase 
ER (Gurney and Thomas, 2011). This chain of events is repeated until the polyketide has 
reached the required length. Because the mup cluster lacks an obvious loading module, 
loading is proposed to happen through mmpC that encodes MmpC, which consists of two 
AT domains (AT1 and AT2). AT1 is thought to work as acyl hydrolase and AT2 exhibits 
malonyl tranferase activity. These two AT domains are proposed to catalyse the transfer of 
starter and extender unit (in-trans) to KS and ACP respectively via acyl-CoA activated 
intermediates between condensation modules (Figure 1.10) (El-Sayed et al., 2003). 
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1.3.2.1 Biosynthesis of the monic acid backbone 
 
The mupirocin biosynthetic pathway is not collinear with the gene sequence, 
since the first condensation modules are found on MmpD despite MmpA being the first 
gene to be transcribed. This was confirmed by mutation of the KR4 active site tyrosine to 
phenylalanine, which resulted in the mutated strain not producing any pseudomonic acid A 
but instead producing mupiric acid.  Six condensations take place in order to synthesise the 
heptaketide chain that forms the monic acid skeleton (Thomas et al., 2010). A proposed set 
of steps for monic acid biosynthesis start with a trans AT located in MmpC transferring an 
activated starter unit (thought to be acetyl-coenzyme A) to the 4-phosphopantethine arm of 
ACP-D1. The chain is then moved to the thiol group of the active cysteine on KS-D1. Now 
that the ACP-D1 is vacant, the activated extender unit (malonyl-CoA) is transferred to the 
4-phosphopantethine arm of ACP-D1, followed by Claisen condensation catalysed by KS-
D1. Another possible scenario could be that the activated starter unit is directly transferred 
to KS-D1 or possibly that it is loaded onto one of the type II ACPs of the “tailoring 
region” and then transferred to KS-D1. This first module of MmpD creates the isoleucine-
like side chain structure by the action of KR and α-methylation. To form the C12 unit the 
chain undergoes three rounds of condensation on the KSs and ACPs (modules 2 to 4) of 
MmpD and another α-methylation which takes place on MT in module 3. The intermediate 
is then thought to be transferred across from MmpD to the first module of MmpA, which 
is thought to be non-elongating due to its atypical domains (KS0 and ACP). Although the 
KS0 has Gln instead of His which could mean that it is not functioning in a normal way, 
mutation of KS0 results in a Mup- phenotype (El-Sayed et al., 2003). It could be that the 
KS0 is a pseudo-loading module that aids the chain transfer from MmpD to MmpA.  Two 
more elongations plus the final beta-branching are performed to extend the chain to 
produce the C17 which is a precursor to the monic acid. 
34 
 
1.3.2.2 Tailoring the monic acid backbone 
 
Post PKS tailoring is a significant part of the polyketide biosynthetic pathway as 
it is one of the factors that make polyketides such a diverse group in terms of structure or 
activity. Post PKS modifications may include addition of moieties like sugars units, 
halogenation, methylation or cyclisation, while further oxidative or reductive steps might 
also occur in order to produce the complete metabolite. The tailoring region in the mup 
cluster comprises 26 ORFs (mupC-X, and macpA-E), in addition to mmpE and mmpF. The 
tailoring activities might take place either before or after esterification of the monic acid 
and 9-hydroxynonanoic acid. Initially the epoxide ring is created by oxidation of the C-
10,11 double bond (Cooper et al., 2005a, El-Sayed et al., 2003). Reduction of C-8,9 
double bond and oxidation of C-16 creates the tetrahydropyran ring, in addition the 
hydroxylation of C-6 and addition of the C-15 methyl group. Although it appears that the 
number of tailoring enzymes exceeds that of the predicted steps needed for the formation 
of the complete polyketide, it has been proven that they are indeed all essential for the 
synthesis of the main metabolite pseudomonic acid A. Mutagenesis of mupT and mupW, 
which are putative dioxygenases, produced a novel pseudomonic acid (mupirocin W) that 
lacks the tetrahydropyran ring, but has the 9-hydroxynonanoic acid chain attached. 
Therefore, it seems like mupW and mupT have the function of catalysing the epoxidation 
of C-8,16 double bond which is proposed to be essential for the tetrahydropyran ring 
formation. This confirmed their role in mupirocin biosynthesis, but without a clear 
indication as to when this step normally occurs (Cooper et al., 2005a, El-Sayed et al., 
2003). To test the significance of other tailoring genes, mutagenesis studies were carried 
out to include mutations in mupQ, S, T, R, X and I. The results showed that all the genes 
are required for normal pseudomonic acid production, but that they might differ in the 
level of impact their deletion would have on pseudomonic acid production (Cooper et al., 
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2005b). In order to produce pseudomonic acid A it is proposed that MupU facilitates the 
transfer to mAcpE, prior to MupO catalysing the oxidation of the C-7 hydroxyl to ketone. 
This is followed by C8-9 dehydration by MupV to create the enoyl bond. The final steps 
before formation of pseudomonic acid A is the reduction of C-8-9 by MupC and 
ketoreduction at C-7 by MupF. When mupO, mupU, mupV, or macpE were deleted 
pseudomonic acid A production was not only abolished, but the pathway was shifted to 
produce pseudomonic acid B (80%, 87%, 137% and 60% compared to the wild type 
respectively). This finding might imply that the protein product of these genes are all 
involved in the same biosynthetic step, which could explain why there appear to be more 
tailoring genes than should be needed for the additional modification steps to produce a 
completed functional polyketide chain (Cooper et al., 2005b). Other modifications to the 
mupirocin backbone includes the incorporation of β-methyl group at C-15, this is catalysed 
by the genes in the HCS cassette (Haines et al., 2013). 
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1.3.2.3 9-hydroxynonanoic acid biosynthesis 
 
The current hypothesis for the 9-hydroxynonanoic acid biosynthesis is that the 
starter unit is 3-hydroxypropionic acid. This process involves three iterative condensation 
reactions, and a complete reduction of the keto groups by the action of ketoreductase, 
dehydratase and enoyl reductase. Previous studies have identified MmpB as a likely 
candidate for the three iterative condensations using malonate as an extender unit. 
Although MmpB lacks an obvious ER domain, the enoyl reduction step might be carried 
out by MupE, which shows a high degree of sequence similarity to known enoyl 
reductases (El-Sayed et al., 2003, Gurney and Thomas, 2011, Thomas et al., 2010). Being 
the last enzymatic reaction involved in the 9-hydroxynonanoic acid reduction it was 
expected that the absence or inactivity of MupE (enoyl reductase) would result in a fully 
unsaturated fatty acid, if it were the only enzyme involved. However, this was not 
observed when mupE was mutated suggesting that there is an additional enzyme involved 
in this process (El-Sayed et al., 2003). Further investigation revealed a third domain in 
MmpC that could participate in the formation of 9- hydroxynonanoic acid, because it also 
shows similarity to enoyl reductases.  The presence of the three tandem ACPs could also 
indicate that MmpB is associated with 9-hydroxynonanoic production as they could be 
used successively to complete the three rounds of condensation (Cooper et al., 2005b, El-
Sayed et al., 2003). Experiments conducted to find out more about how this ACP triplet 
works have shown that point mutations in the active site of acp5S>A abolished mupirocin 
production, while point mutation in each of acp6 and acp7 had much less effect on 
mupirocin levels. On the other hand, while deleting one of the ACPs in mmpB slightly 
reduces mupirocin production, pairwise deletions e.g. (Δmacp5/6, Δmacp6/7, Δmacp5/7) 
significantly decreased mupirocin production. Therefore, it seems that any one of the 
doublet and the triplet ACPs is sufficient for the formation of the polyketide chain, but that 
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reduction of the triplet cluster to a single mACP does have a quantitative effect on 
production (Rahman, 2005).   
 
Figure 1.12 Quantitative HPLC analysis of PA-A production in each of the ACP mutants 
(Rahman, 2005). 
 
The final polyketide product is either released by the only TE in the pathway 
located in MmpB or it is possible the TE might play a role in the esterification of 9- 
hydroxynonanoic acid. It is still not clear whether 9-hydroxynonanoic acid is produced 
first and then joined to monic acid or 9- hydroxynonanoic acid is elongated on C3 starter 
unit 3-hydroxypropionate esterified with the monic acid produced by MmpD/MmpA (El-
Sayed et al., 2003, Hothersall et al., 2007) (Cooper et al., 2005b). 
 
1.3.3 Regulation of Mupirocin production 
 
Quorum sensing is a mechanism that allows bacteria to control gene expression 
through constitutive production of autoinducers, which once a critical population density is 
reached accumulates to a sufficient concentration to trigger the required response (Kuo et 
al., 1994). In the case of mupirocin, quorum sensing involves the production of N-acyl 
homoserine lactones (NAHL) that build up to induce enough mupirocin production to kill 
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surrounding bacteria (El-Sayed et al., 2001). In this regard, Vibrio fischeri is a typical 
representative of this kind of gene expression, where the autoinduction of the lux regulon 
is responsible for bioluminescence (Miyashiro and Ruby, 2012). In the mupirocin system, 
MupI and MupR sequences show similarity to LuxI and LuxR which mediate the response 
to homoserine lactones (Thomas et al., 2010). It is predicted that the NAHL produced by 
MupI binds to MupR in order for the latter to bind to the promoter and activate 3-oxo-C10 
N-acyl homoserine lactone (El-Sayed et al., 2001, Thomas et al., 2010).  To test if the mup 
cluster was regulated by quorum sensing mechanism, the xylE gene encoding catechol 2, 
3-dioxygenase was used as a reporter gene at different places in the mup cluster. While 
deletion of mupI abolished synthesis of homoserine lactone in P. fluorescens, providing 3-
oxo-C10 N-acyl homoserine lactone exogenously restored the function proving that mup 
cluster is controlled by quorum signal. Since MupR controls the putative regulatory region 
upstream of mupA and the region between mupF and macpC, it is plausible that the mup 
cluster might be transcribed as one long unit through the MupR/MupI system binding to 
the promoter regions upstream of mupA, macpC and mupF.  The mup cluster might also be 
regulated by mupX, as it appears that inactivating it reduces mupirocin production by about 
40%. Inactivation of mupX does not have any effect on the product profile, but it might be 
required for the expression of other genes in the mup cluster (El-Sayed et al., 2001, 
Hothersall et al., 2011). Expressing mupR in-trans resulted in an almost fivefold increase 
in mupirocin production, in addition to some early intermediates like mupiric acid, 
mupirocin H and truncated products of PA-A and PA-B. (Hothersall et al., 2011). 
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1.3.4 Clinical significance  
Mupirocin works by binding to the bacterial isoleucyl-tRNA synthetase, which 
consequently leads to competitive inhibition of protein synthesis in the bacterial cell. The 
C12 to C14 terminus of the monic acid resembles the hydrophobic side chain of 
isoleucine; the pyran ring interacts with the ATP-binding pocket of IleRS. It is proposed 
that the 9-hydroxynonanoic acid would fit into a hydrophobic groove to help in the binding 
process, and stabilise the complex (Figure 1.13) (Thomas et al., 2010). To prevent protein 
synthesis, mupirocin thus acts as an analogue of lle-AMP, and blocks the binding of the 
activated amino acid to the catalytic cleft of the Rossman fold domain of lleRS. This in 
turn  mimics the effect of isoleucine starvation, triggering the stringent response, which 
down-regulates many functions in the bacterial cell including protein synthesis (Thomas et 
al., 2010) (Cassels et al., 1995).  
Mupirocin was discovered in 1971 and it was first introduced into clinical 
practice in the UK in 1985 (Fuller et al., 1971). Since the early stages of its introduction 
mupirocin has demonstrated many properties that are advantageous for a topical antibiotic, 
such as low resistance rate in common cutaneous pathogens, and a lack of cross resistance 
to other agents (Cookson, 1990). In a study to determine the effectiveness of mupirocin in 
clinical settings, it was found that mupirocin provides protection against S. aureus 
infection, especially in dialysis patients and ICU populations (Nair et al., 2015). Mupirocin 
is also successfully used as a nasal ointment to decolonize nasal passages to control 
asymptomatic MRSA carriage (van Rijen et al., 2008). Mupirocin is widely used outside 
healthcare settings to manage community-acquired MRSA. However, although considered 
an ideal topical antibiotic, studies have shown that the long term use of mupirocin can 
promote S. aureus resistance, rendering it unsuitable for prolonged treatments (Thomas et 
al., 2010).  
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Figure 1.13 Mupirocin mode of action.  Mupirocin bound in the synthetic site of 
isoleucyl-tRNA synthetase (from Thomas et al., 2010) (Hurdle et al., 2004, Silvian et al., 
1999). 
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1.3.5 Resistance to mupirocin 
 
In 1987, two years after the introduction of mupirocin, resistance began to 
emerge. Two phenotypes of mupirocin resistance have been identified: low level 
mupirocin resistance (8-256mg/L) and high level mupirocin resistance (>256mg/L) (Patel 
et al., 2009). High level mupirocin resistance is usually associated with mupirocin 
decolonization failure. Strains with high level mupirocin resistance are the result of the 
presence of IleRS proteins which are similar to eukaryotic IleRS that are naturally resistant 
to much higher levels of mupirocin acquired by horizontal gene transfer (Thomas et al., 
2010). In S. aureus eukaryotic-like IleRS is encoded by mupA on conjugative plasmids that 
confer high level mupirocin resistance, as well as other antimicrobial agents like 
macrolides, tetracycline, gentamicin and trimethoprim (McNeil et al., 2011, Oliveira et al., 
2009). Two distinct IleRS enzymes are responsible for S. aureus strains with high level 
mupirocin resistance. One is a mupirocin resistant enzyme encoded by the plasmid ileS-2 
and the mupirocin sensitive enzyme encoded by the chromosomal wild type ileS-1. Recent 
studies have also identified an additional gene responsible for high-level mupirocin 
resistance (mupB), which contains conserved motifs found in class I tRNA synthetases 
(Seah et al., 2012) (Ramsey et al., 1998). On the other hand, spontaneous point mutations 
in the chromosomal ileS result in low level mupirocin resistance. These mutations occur in 
the Rossman fold and close to the conserved motif KMSKS, which is involved in 
determining the binding of the 9-hydroxynonanoic acid moiety and ATP. The most 
common mutations associated with low level mupirocin resistance are the Val to Phe 
substitutions, especially the V588F and V631F (Silvian et al., 1999, Hurdle et al., 2004). 
The crystal structure of the IleS, tRNA and mupirocin complex revealed that when valine 
is substituted with phenylalanine, the much bulkier benzyl side chain of the latter disrupts 
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the hydrophobic pocket inside the Rossman fold, which is critical for mupirocin binding 
(Antonio et al., 2002).  
1.3.6 Non-ribosomal peptide synthases 
 
Similar to the PKS system, NRPSs contain modules, which are responsible for 
incorporating building blocks into the growing polypeptide chain. The size of the resulting 
product varies, but they can reach remarkably large sizes like the 1.6 MDa cyclosporin 
NRPS, which comprises 11 modules all synthesised by a single NRPS protein in 
Tolypocladium niveum. In bacteria on the other hand, modules are distributed over several 
NRPSs, which are usually arranged into operons. Pseudomonas syringae has one of the 
largest bacterial NRPS systems, containing 8 modules (Evans et al., 2011). A minimum of 
three domains is required to achieve a functional NRPS, an Adenylation (A) domain, a 
Peptidyl Carrier Protein (PCP) and a Condensation (C) domain for the peptide bond 
formation. A-domains are responsible for activating carboxy acid substrate to amino acyl 
adenylate while ATP is being consumed. The PCP-domain acts as a transport unit that 
accepts the activated amino acid that is covalently tethered to its 4´-phoshopantetheine 
cofactor as thioester. This cofactor is post-translationally transferred to a conserved serine 
residue of the carrier protein (CP), and acts as a flexible arm to allow the bound amino 
acyl and peptidyl substrate to travel between different catalytic centres. The next step in 
NRPS synthesis is carried out by the condensation domain, which is responsible for the 
peptide bond formation. This is achieved by catalysing the nucleophilic attack of the 
amino group of the activated amino acid bound to downstream module, onto the acyl 
group of the amino acid attached to the upstream module. During synthesis, the growing 
peptide chain is handed over from one module to the next until it reaches the final module 
in PCP-domain. This module contains in most cases a TE-domain that is important for 
product release (Figure 1.14). 
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TE-independent termination has also been observed in some NRPS systems like 
in myxochelin biosynthetic pathway, in which an aldehyde is produced through the action 
of the reductase that catalyses the thioester reduction. The final product can be either 
released as a macrocyclic product such as in surfactin, or a linear peptide as in pyochelin.  
 
Figure 1.13 Nonribosomal peptide synthetase (NRPS) assembly line.  The peptidyl 
carrier domain (PCP) has a phosphopantetheine prosthetic group terminated with a thiol. 
The adenylation (A) domain activates amino acids and the condensation (C) domain makes 
the amide linkages. Termination is frequently catalyzed by a thioesterase (TE) domain 
(from Condurso & Bruner, 2012). 
 
1.3.7 Thiomarinols  
 
Thiomarinols are antibiotics produced by marine bacteria Pseudoalteromonas 
rava sp and Pseudoalteromonas luteoviolacea. Structurally, thiomarinol is a combination 
of two separate classes of antibiotics, pseudomonic acids and pyrrothines (Shiozawa et al., 
1993). From a biosynthetic point of view, thiomarinols are considered to have three 
elements: a functionalised polyketide acid, linked by ester to a hydroxyl fatty acid, in turn 
linked by amide to pyrrothine. Thiomarinols are active against both Gram positive and 
Gram negative bacteria (Murphy et al., 2014), and importantly they are potent against 
Staphylococcus aureus (MRSA). It is thought that its additional potency against Gram 
negative bacteria is due to either increased uptake, as Gram negative bacteria are protected 
by the outer membrane, or because of the holomycin part which inhibits RNA synthesis, 
and provides a second target besides the isoleucyl-tRNA synthetase (Fukuda et al., 2011, 
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Murphy et al., 2011). It is worth mentioning that at least in Gram negative bacteria 
resistance is conferred by a single gene, tmlM which encodes an IleS, suggesting that the 
potency is not the result of attacking more than one target. Previous work on the 
thiomarinol biosynthetic pathway showed that thiomarinol was more active in terms of 
inhibiting MRSA growth than the pyrrothine amides. Marinolic acid (produced by the 
trans-AT PKS part and the equivalent to pseudomonic acid or mupirocin) showed less 
activity than mupirocin which suggests that the addition of the pyrrothine (produced by the 
NRPS part) is the reason for thiomarinol’s increased potency (Fukuda et al., 2011). 
Thiomarinol differs from mupirocin in having 8-hydroxyoctanoate instead of the 9-
hydroxynonanoic acid, the presence of an extra 4-hydroxyl group, pyrrothine and the lack 
of the 10,11 epoxide ring. All of which may contribute to the differences in activity 
(Fukuda et al., 2011).  
 
Figure 1.14 Chemical structures of mupirocin and thiomarinol.  The structures 
highlight the differences between these two compounds. Monic acid and the 8-
hydroxyoctanoic acid combined are the equivalent to pseudomonic acid/mupirocin. 
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The thiomarinol biosynthetic pathway appears to be entirely encoded on a 97,600 bp 
plasmid (pTML1) that includes 27 ORFs, with trans-AT PKSs (tmpA to tmpD)  
responsible for the marinolic acid part (Fukuda et al., 2011). The other part of the plasmid 
encodes the 7 NRPS-encoding ORFs that are thought to be responsible for pyrrothine 
production. Sequencing data showed a great similarity to the mup cluster, but also some 
intriguing differences between the two systems. One difference is the absence of an macpE 
equivalent in thiomarinol cluster. In the mupirocin pathway, the protein mAcpE is thought 
to accept the polyketide intermediate from MupU, which is then processed by MupO, V, C 
and F (Fukuda et al., 2011).  In thiomarinol biosynthesis, there is instead an extra module 
consisting of a KS and ACP in TmpB, which might be involved in the equivalent final 
tailoring steps in marinolic acid biosynthesis. Extra ACP domains can be seen in several 
modules like the third module of TmpD and the last module of TmpA, a possible function 
could be increasing the pathway’s throughput (Figure 1.15). It is worth mentioning that 
SANK73390-tmpD mutants produced only yellow pigmented pyrrothine material, while 
SANK73390-holA mutants produced only marinolic acid. This observation indicates that 
marinolic acid and pyrrothine are produced separately and then joined together by the 
action of TmlU, which activates the pseudomonic acid as a thioesterase, and HolE which 
catalyses the amidation as an acyltransferase (Figure 1.16) (Fukuda et al., 2011) (Dunn et 
al., 2015). 
Although no obvious regulatory protein was found in pTML1, four of the five 
transcriptional units have likely operator sequences through which the genes are regulated 
(Fukuda et al., 2011).  Mutasynthesis studies on the Thiomarinol cluster yielded a number 
of different metabolites, which can provide more clues into how to genetically engineer 
SANK73390 in order to produce new antimicrobial compounds active against MRSA 
(Murphy et al., 2011, Murphy et al., 2014, Fukuda et al., 2011).  
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Figure 1.15 Predicted scheme for thiomarinol biosynthesis  showing the roles of TmpD 
(modules 1 to 4)/TmpA (modules 5 and 6) for monic acid, TmpB for 8-hydroxyoctanoic 
acid and HolA/NRPS for pyrrothine. Cy, Condensation domain; A, Aminoacyl 
Adenylation Domain; T, Thiolation Domain or Peptidyl Carrier Protein (from Fukuda et 
al., 2011). 
 
 
Figure 1.16 HPLC analysis of products from wild type Pseudoalteromonas rava 
SANK 73390 and mutant derivatives. In the absence of TmlU, the amide bond between 
marinolic acid and pyrrothine is not formed (from Fukuda et al., 2011). 
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Table 1.2 Predicted gene products on pTML1 (Fukuda et al., 2011) 
Gene name  Predicted function 
tmlN Phosphopantetheinyl transferase 
tmlT Ferredoxin dioxygenase 
intA similar to phage integrase 
orfA N-terminal of transposase 
repA Plasmid replication initiator  
parA ATPase, partitioning  
parB DNA binding, partitioning  
tacpB Acyl carrier protein 
tmpF Ketosynthase domain 
tacpD Acyl carrier protein 
tmlS 3-oxoacyl-ACP reductase 
tmlQ Acyl-CoA synthase 
tmlM Isoleucyl tRNA synthase 
tmlA FMNH(2)-dependent oxygenase 
tmpA Multifunctional PKS 
tacpC Acyl carrier protein 
tmlG 3-oxoacyl-ACP synthase 
tmlH HMG-CoA synthase 
tmlJ Enoyl-CoA hydratase 
tmpE Enoyl-CoA hydratase and ketosynthase 
tmlL Putative hydrolase 
tmpB Multifunctional PKS 
tmpC Trans acyl-transferase plus putative enoyl reductase  
tmpD Multifunctional PKS 
tmlB 3-oxoacyl-ACP synthase 
tmlC NADH: flavin oxidoreductase  
tmlF Ketoreductase 
tmlP Unknown 
tmlO Cytochrome P450 
tmlU Acyl-CoA synthase 
tmuA  Membrane protein / Permease 
tmlY Unknown 
tacpA Acyl carrier protein 
tmuB Putative dioxygenase 
tmlW Dioxygenase (Rieske 2Fe-2S protein) 
tmlZ Chromosomal replication initiation protein 
holA Non-Ribosomal Peptide Synthase 
holB Oxidoreductase 
holC Thioesterase 
holD Acyl-CoA dehydrogenase 
holE Acetyltransferase 
holF Truncated Globin/ Monooxygenase 
holG Decarboxylase; flavoprotein 
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1.4 Aminocoumarin  
The aminocoumarin class of antibiotics, produced by different strains of 
Streptomyces, consists of compounds structurally similar to each other. These possess the 
same unique feature, the 3-amino-4,7-dihydroxycoumarin moiety; examples include 
novobiocin, chlorobiocin, coumermycin A1 and simocyclinone (Heide, 2009a). The 
biosynthetic gene clusters for each have been sequenced, and several genes encoding 
important enzymes have been identified. These include the amide synthetases NovL, CloL, 
CouL and SimL, which are responsible for creating an amide bond during biosynthesis of 
aminocoumarin antibiotics. Interestingly, a similar gene (tmlU) was found in the 
biosynthetic gene cluster of thiomarinol. This finding suggested the possibility that SimL 
(the most similar of these amide synthetases) or others of this group might be able to 
replace TmlU in SANK73390 (Fukuda et al., 2011). Aminocoumarins are produced by 
different strains of Streptomyces and they target bacterial gyrase, which is an essential 
enzyme for DNA replication and transcription in bacteria (Luft et al., 2005).  
Aminocoumarin antibiotics are a successful example of generating a hybrid antibiotic 
using the mutasynthesis procedure. Heide and coworkers were able to demonstrate that by 
feeding a synthetic precursor (Ring A), necessary for the biosynthesis of the prenylated 4-
hydroxybenoate moiety of clorobiocin, to a strain with an engineered novobiocin 
biosynthetic gene cluster, they could produce analogs of the novobiocin glycon 
(novobiocin acid) (Heide, 2009). The next step was the addition of the culture extract from 
the first feeding to another strain unable to produce clorobiocin, and this formed the 
deoxysugar, the 4-methyl group and the 5-methylpyrrolle-2-carbonyl moiety, which is 
characteristic of clorobiocin, and attached them to the novobiocin acid analog. Thus, this 
procedure led to the generation of a hybrid antibiotic that possessed the structural features 
of both novobiocin and clorobiocin (Anderle et al., 2007b).   
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Figure 1.17 Structures of the aminocoumarin antibiotics. clorobiocin, novobiocin, 
coumermycin    A1, simocyclinone D8 and simocyclinone D4 (from Heide, 2009b). 
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1.5 Statement of objectives 
With antibiotic resistance on the rise, different approaches have been utilized to 
tackle this problem, most of which depend on creating semi-synthetic molecules using 
existing antibiotics as a scaffold.  As genomic sequencing has become cheaper and faster, 
and sequences of many antibiotic-producing bacteria are readily accessible, combinatorial 
biosynthesis approaches became more popular as a means to produce novel antimicrobial 
molecules. This was achieved by genetically manipulating the biosynthetic pathways of 
different systems and creating hybrid compounds with new and more efficient properties. 
Examples of hybrids that might be useful include, mupirocin derivatives lacking the ester 
bond that could be used systemically, or a hybrid of thiomarinol and mupirocin, where 
thiomarinol activity is not toxic to the eukaryotic cells but still has the antimicrobial 
activity of both of the molecules combined. Research in the Thomas lab at the University 
of Birmingham has been focused on understanding the biosynthetic pathway of Mupirocin 
to underpin development of such derivatives. Although most of the biosynthetic pathway 
has been elucidated, there are still some aspects that need to be further investigated in 
order to rationally design hybrid pathways producing novel antimicrobial compounds. 
The initial objective of this project (chapter 3) was to investigate the possibility of 
incorporating amide synthases from different polyketide pathways into the mupirocin 
biosynthetic pathway. The background for this is derived from the role that these amide 
synthetases play in their native systems. SimL for example, is an essential enzyme that 
assembles simocyclinone, which bears a structural resemblance to both mupirocin and 
thiomarinol. Likewise, in the thiomarinol pathway TmlU is one of the enzymes involved in 
linking pseudomonic acid to holomycin creating thiomarinol. The hypothesis investigated 
in chapter 3 is whether SimL and other similar amide synthetases can catalyse the 
attachment of parts of mupirocin to thiomarinol. To test this, several amide synthetases 
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were identified, and cloned into an expression vector to be provided in-vivo in-trans to the 
mupirocin and thiomarinol producing strains. Effects of in-trans expression of these 
proteins could then be detected by HPLC analysis. 
Expression of TmlU in the mupirocin producer was observed to inhibit normal 
production of pseudomonic acid A (chapter 3). This was of interest, as understanding the 
mechanism of this inhibition could yield insight into how TmlU functions in thiomarinol 
biosynthesis, and how it interacts with different elements of the mupirocin pathway. When 
TmlU was expressed in the mupirocin producer, truncation of the fatty acid produced by 
MmpB was observed. This lead to the hypothesis that TmlU inhibits mupirocin production 
through interaction with MmpB. In chapter 4, this hypothesis is investigated through 
testing the effect of mutations of both MmpB and TmlU on pseudomonic acid A 
production. These mutations would allow insight into the mechanism by which TmlU 
inhibits mupirocin biosynthesis, and allow identification of the specific region of MmpB 
putatively responsible for interaction with TmlU. This interaction would then be tested 
using the bacterial two hybrid system to look for protein-protein interactions. 
In thiomarinol biosynthesis, holomycin is produced by a set of NRPS genes, the 
hol genes. It would be desirable to generate holomycin in-vivo in the mupirocin producing 
strain, as this could facilitate generation of a mupirocin-holomycin hybrid in the future. 
The hypothesis of chapter 5 is to demonstrate whether plasmid encoded holomycin 
biosynthesis can occur in the mupirocin producer. To test this, the holomycin operon 
would be cloned into a vector and expressed in-trans in the mupirocin producer. Any new 
compounds produced could be detected by HPLC, and their bioactivity identified by 
bioassay. Holomycin production may also be detectable through a phenotypic shift, due to 
the yellow colour of the compound. 
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While most of the steps in the mupirocin pathway have been elucidated, some of 
the tailoring genes have not yet been assigned a function, and the timing of some steps is 
not yet certain. One function without an assigned gene is the 6-hydroxylation of monic 
acid. Deletion of mupA in the mupirocin producer yielded only mupiric acid, which lacks 
the α-hydroxyl. This suggested the intermediate could not proceed beyond MmpD. One 
hypothesis that could explain this is that the KS2 of MmpA has gatekeeper activity, where 
it demonstrates selectivity for the 6-OH group. Further to this, a loop was identified on 
homology models that could be responsible for this specificity. This led to a second 
hypothesis, can the KS2 be re-engineered to relax this specificity, therefore allowing 
condensation of the non 6-OH intermediate through MmpA. To test these hypotheses, 
chromosomal mutations would be made to swap regions of other MmpA KS domains into 
KS2. These mutant strains would be analysed by HPLC, LC-MS, and NMR where 
necessary, to identify compounds produced. Identification of a full length product lacking 
the 6-OH would indicate both that KS2 has the described gatekeeper activity, and which 
specific region of the protein is responsible for this specificity. 
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CHAPTER 2 
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2 MATERIALS AND METHODS 
 
2.1 Bacterial strains, culture conditions and plasmids 
All the bacterial strains used in this study are listed in Table 2.1. L-broth and L-
agar, (Bertani, 1951) were used to grow P. fluorescens NCIMB10586 at 30°C 
supplemented with 50µg/ml ampicillin; antibiotics used in this study are listed in Table 
2.2.  Chemical reagents used in this study were purchased from Sigma-Aldrich. 
Recombinant DNA was transformed initially into Escherichia coli DH5α for plasmid 
propagation and sequencing. E. coli S17-1 was used to mobilise vectors/plasmids into P. 
fluorescens NCIMB10586 by conjugation. The conjugants were then plated on M9 
minimal media: 200ml salt solution containing NA2HPO4 (6g/l), KH2PO4(3g/l), NH4Cl 
(1g/l), MgSO4(1mM), thiamine HCl (1mM), CaCl2(0.1mM), glucose (0.2%) added to 
200ml 50% H2O agar) and left for 2-3 days to grow at 30°C. Bioassays for mupirocin 
production were performed using Bacillus subtilis 1064 as an indicator strain, which was 
grown at 37°C in L broth overnight. To introduce changes into the chromosomal DNA the 
plasmid pAKE604 was utilised as a suicide vector.  Plasmid pET28 was used in site-
directed mutagenesis to introduce deletions and mutations into plasmids. 
Pseudoalteromonas spp. SANK 73390 is the producer of thiomarinol and was grown in 
marine agar or marine broth at 23°C. Marine broth contains 33.33g of sea salt in 1 L 
distilled water, 5g bacteriological peptone, 0.1g ferrous sulphate and 0.89g yeast extract 
(Shiozawa et al., 1993). For marine agar 15g of agar powder is added to the previous mix.  
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Table 2.1 Bacterial strains used in this study 
Bacterial strain Genotype/phenotype source 
E. coli 
DH5α 
Ф80lacZ∆M15, recA1, 
endA1, gyrA86, thi-1, 
HsdR17(r kˉ, m k+), supE44, 
relA1, deoR, ∆(lacZYA- 
ArgF)U169 
 
Gibco BRL 
P. fluorescens 
NCIMB10586 
Wild type (W.T) strain 
which produces mupirocin 
 
G. T Banks 
Escherichia coli 
S17-1 
recA pro hsdR RP4-2-
Tc::Mu-km::TAN7 Simon et al., 1983 
Pseudoalteromonas 
SANK73390 
Wild type (W.T) strain 
which produces Thiomarinol 
Daiichi Sankyo Co., Ltd 
B. subtillis 
rpC2amyE::(spec P 
xyl-gfp-lacI) chr::pSG1196 
(rrnD-lacO cat 
 
Moir et al., 1979 
 
P. fluorescens 
NCIMB10586∆ACP5 
(ACP-Ba)(mmpB) 
 
P. fluorescens with 
ACP5(mmpB) deletion  
 
Rahman et al.,  
2005 
(C.M. Thomas lab) 
P. fluorescens 
NCIMB10586∆ACP6 
(ACP-Ba)(mmpB) 
 
P. fluorescens with 
ACP6(mmpB) deletion  
 
Rahman et al.,  
2005 
(C.M. Thomas lab) 
P. fluorescens 
NCIMB10586∆ACP7 
(ACP-Ba)(mmpB) 
 
P. fluorescens with 
ACP7(mmpB) deletion  
 
Rahman et al.,  
2005 
(C.M. Thomas lab) 
P. fluorescens 
NCIMB10586ΔmupA 
P. fluorescens strain with 
mupA deletion 
Joanne Hothersall 
(C.M. Thomas lab) 
 
 
57 
 
 
 
Table 2.2 Antibiotics used in this study 
Antibiotic 
Working concentration 
(µg/ml) 
Solvent 
Ampicillin 50 H2O 
Chloramphenicol 50 70% (v/v) Ethanol 
Kanamycin sulphate 50 H2O 
Tetracycline hydrochloride 15 70% (v/v) Ethanol 
 
Table 2.3 Plasmids used in Chapter 3. 
Plasmid 
Size 
(kb) 
Properties Source 
pJH10 13.76 
IncQ replicon,multiple cloning site 
(EcoRI-SacI),TetR 
 
El-sayed et al., 
2011 
pJH10-Xho1-
linker 
14.5 
IncQ replicon, multiple cloning site 
(EcoRI-SacI), TetR with Xho1-linker 
 
Hothersall et al., 
2007 
pGEM-T-
Easy 
3.0 AmpR , tac promoter, N-terminus 
GST.TAG 
G.E. Healthcare 
pAMH1 16.4 1.96 kb EcoRI-SalI fragment containing 
tmlU cloned into pJH10-Xho1-linker 
Omer-Bali thesis 
2013 
pSIML 15.26 1.5 kb EcoRI-XbaI fragment of simL 
cloned into pJH10 
This study 
pNOVL 15.30 1.54 kb EcoRI-XbaI fragment of novL 
cloned into pJH10 
This study 
pCLOL 15.27 1.51 kb MfeI-XbaI fragment of cloL 
cloned into pJH10 
This study 
pCOUL 15.27 1.51 kb MfeI-XbaI fragment of couL 
cloned into pJH10 
This study 
pGEMSM 4.5 1.5 kb EcoRI-XbaI fragment of simL 
cloned into pGEM-T-Easy 
This study 
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pGEMNV 4.54 1.54 kb EcoRI-XbaI fragment of novL 
cloned into pGEM-T-Easy 
This study 
pGEMCL 4.51 1.51 kb EcoRI-XbaI fragment of cloL 
cloned into pGEM-T-Easy 
This study 
pGEMCO 4.51 1.51 kb EcoRI-XbaI fragment of couL 
cloned into pGEM-T-Easy 
This study 
Table 2.4 Plasmids used in Chapter 4. 
Plasmid 
Size 
(kb) 
Properties Source 
pJH10 13.76 
IncQ replicon,multiple cloning site 
(EcoRI-SacI),TetR 
 
El-sayed et al., 
2011 
pJH10-Xho1-
linker 
14.5 
IncQ replicon, multiple cloning site 
(EcoRI-SacI), TetR with Xho1-linker 
 
Hothersall et al., 
2007 
pAMH1 16.4 
1.96 kb EcoRI-SalI fragment containing 
tmlU cloned into pJH10-Xho1-linker 
Omer-Bali (2013) 
pET28a 5.3 kanR, His-Tag,T7p,lacI Novagen 
pAKE604 7.2 
pMB1 replicon. AmpR, KmR , oriT, 
lacZα, sacB 
El-Sayed et al., 
2001 
pUT18 3.23 AmpR, CyaA (225- 399), lacI Euromedex 
pKT25 3.442 KanR , CyaA (1-224), lacI  
Euromedex 
pET28a-tmlU 7.2 
1.96 kb EcoRI-SalI fragment containing 
tmlU cloned into pET28a 
Fukuda et 
al., 2011 
pTmlUM1 16.4 
1.96 kb EcoRI-SacI fragment containing 
tmlU with the mutation A>C cloned into 
pJH10-Xho1-linker. 
This study 
pTmlUM2 16.4 
1.96 kb EcoRI-SacI fragment containing 
tmlU with the mutation GA>GT Cloned 
into pJH10-Xho1-linker 
This study  
pTmlUM3 16.4 
1.96 kb EcoRI-SacI fragment containing 
tmlU with the mutation AAG>AGG 
Cloned into pJH10-Xho1-linker 
This study 
pTEMD 8.219 
1kb BhamH1-HindIII fragment 
containing TE with the mutation A>C 
cloned into pAKE604 
This study  
pMMH4 19.5 
5kb KpnI-XbaI fragment containing 
mupO, macpE and mupUV cloned into 
pJH10 vector.  
M.Macioszek 
thesis 2009 
59 
 
pUT18tmlU 5.19 
1.96 kb EcoRI-XbaI fragment containing 
TE cloned into pUT18 
This study 
pKT25TE 4.204 
0.762 kb EcoRI-XbaI fragment 
containing TE cloned into pKT25 
This study  
 
Table 2.5 Plasmids used in Chapter 5 
Plasmid 
Size 
(kb) 
Properties Source 
pJH10 13.76 
IncQ replicon,multiple cloning site 
(EcoRI-SacI),TetR 
 
El-sayed et al., 
2011 
pGEM-T-
Easy 
3.0 
AmpR , tac promoter, N-terminus 
GST.TAG 
G.E. Healthcare 
pGEMHol1 8.77 
5.77 kb XhoI-AgeI fragment containing 
part of the hol genes cloned into pGEM-
T-Easy 
This study 
pGEMHol2 6.0 
3 kb AgeI – SbfI fragment containing part 
of the hol genes cloned into pGEM-T-
Easy 
This study 
pGEMHol3 6.0 
3 kb AvrII – SbfI fragment containing 
part of the hol genes cloned into pGEM-
T-Easy 
This study 
pGMTHol 14.77 
11.77 XhoI-BstbI fragment containing 
the complete hol genes cloned into 
pGEM-T-Easy 
This study 
pHolA-H 24.76 
11 kb XhoI-ClaI fragment containing the 
hol genes from A to H cloned into pJH10 
 
This study 
pHolA-
HtmlU 
26.72 
1.96kb XbaI-SacI fragment containing 
tmlU cloned into pHolA-H 
This study 
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Table 2.6 plasmids used in Chapter 6 
Plasmid 
Size 
(kb) 
Properties Source 
pAKE604 7.2 pMB1 replicon. AmpR, KmR , oriT, 
lacZα, sacB 
El-Sayed et al., 
2001 
pAKEKS1 3.0 
1 kb EcoRI-HindIII fragment containing 
KS1 loop in KS2 cloned into pAKE604  
This study 
pAKEKS3 8.77 
1 kb EcoRI-HindIII fragment containing 
KS3 loop in KS2 cloned into pAKE604 
This study 
 
2.2 Polymerase chain reaction (PCR) 
PCR was used to amplify fragments of DNA. Bacterial template DNA was 
prepared by suspending one bacterial colony in 50µl of sdH2O, and then heating at 90°C 
for 6 minutes before centrifugation.  The supernatant was transferred into a clean 
microcentrifuge tube and used as a template. Primers were synthesised by Abingdon 
Health Laboratory Services of the University of Birmingham and were used at a 
concentration of 100pmol/µl. Velocity DNA polymerase from Bioline was used to amplify 
DNA segments for cloning purposes, while Taq polymerase from Invitrogen was used for 
screening. The melting temperature of each primer was calculated using the equation: Tm 
= 4 (G + C) + 2 (A + T) °C and the annealing temperature was calculated accordingly. 
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Table 2.7 Primers used in Chapter 3  
Name 
Template 
DNA 
Sequence Purpose 
Restriction 
sites 
SIMLF 
pET28-
simL 
GCCGAATTCATGAAACACCACCA
CCACCACCACC Clone 
simL 
into 
pJH10 
EcoRI - 
XbaI 
SIMLR 
GTGTCTAGATCA TTC GCC ATG 
CGT GGC CTC CC 
NOVLF 
pET28-
novL 
GCCGAATTCGTGGCGAACAAGGA
TCACGC  
 
Clone 
novL 
into 
pJH10 
EcoRI - 
XbaI 
NOVLR 
GTGTCTAGATCACCTGTCCACCAG
GACGTC  
 
CLOLF 
pET28-
cloL 
GCCCAATTGGTGGCGAACAAGGA
CCACG  
 
Clone 
cloL into 
pJH10 
MfeI- XbaI 
CLOLR 
GTGTCTAGATCACCTGTCCACCAG
CACGTC  
 
COUL 
pET28-
couL 
GACCAATTGGTGGCGAACAGGGA
CCACG  
 
Clone 
couL 
into 
pJH10 
MfeI- XbaI 5’  
GTGTCTAGATCACCTGTCCACCAG
CACGTC 3’ 
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Table 2.8 Primers used in Chapter 4 (mutated nucleotides are highlighted in RED) 
Name 
Template 
DNA 
Sequence Purpose 
Restric
tion 
sites 
a1379cF 
pET28-tmlU 
GTTGGTTAAATACCGGAGCTC
TTGGCAAGTTCGATGC 
Introduce a 
point mutation 
in tmlU 
N/A 
a1379cR 
GCATCGAACTTGCCAAGAGCT
CCGGTATTTAACCAAC 
g1378a_a
1379g F 
pET28-tmlU 
AGAACCAGGTTGGTTAAATAC
CGGAAGTCTTGGCAAGTTCGA
T  
Introduce a 
point mutation 
in tmlU 
N/A 
g1378a_a
1379g R 
ATCGAACTTGCCAAGACTTCC
GGTATTTAACCAACCTGGTTC
T  
a698gF 
pET28-tmlU 
AACCACGGGAACACCAAGGA
TTGCAAGACATACAC  Introduce a 
point mutation 
in tmlU 
N/A 
a698gR 
GTGTATGTCTTGCAATCCTTG
GTGTTCCCGTGGTT  
dTEaF 
(arm1) 
P. fluorescens 
NCIMB10586 
GCCGGATCCCTGGTC 
GATCAAGTGC AGGGCTGGCT  
Introduce 
mutation to TE 
in P. 
fluorescens 
10586  
BamHI
-HindII 
dTEaR 
(arm1) 
GAGGCACATAGAAAAAGCTG
GCGAGCATGAACAAC 
dTEaF 
(arm2) 
GTTGTTCATGCTCGCCAGCTTT
TTCTATGTGCCTC  
dTEaR 
(arm2) 
GGCAAGCTTCCGCTCCACCTT
CAGAATTCGCCTGC 
hTEaF 
(arm1) 
P. fluorescens 
NCIMB10586 
GCCGGATCCTGGATACGCAGG 
CACCGCCAGATCTG 
Introduce 
mutation to TE 
in P. 
fluorescens 
10586 
BamHI
-HindII 
hTEaR 
(arm1) 
TAGCGCGCCAGGGTGGCGGG
AAGACTGCTTGC 
hTEaF 
(arm2) 
GCAAGCAGTCTTCCCGCCACC
CTGGCGCGCTA 
hTEaR 
(arm2) 
GGCAAGCTTCTCGATCAGCGA
CTGCGCCAACGCATA 
tmlUF 
SANK73390 
GGCTCTAGAGATGAATGAGTC
AGCCCTTAACCC Clone tmlU 
into pUT18 
XbaI-
EcorI 
tmlUR 
GCGGAATTCGATGACTCCAGT
ACAGTTTGCTCA 
TEF 
SANK73390 
GGCTCTAGAGTCGCTGGCGGG
CGCGGACTCGCC Clone TE into 
pUT18 
XbaI-
EcorI 
TER 
GCGGAATTCTTTAATGGGGGC
TCGCGGTCAGG 
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Table 2.9 Primers used in Chapter 5 
Name 
Template 
DNA 
Sequence Purpose 
Restriction 
sites 
HOL1F 
SANK73390 
GCGCTCGAGGGAGTTATATTA
TGAACATGGATGCATTTAAG 
Clone 
the 
HOL1 
fragment 
into 
pGEM-
T-easy 
XhoI-AgeI 
HOL1R 
CCGACCGGTCCCTCGGTTTTC
TAATATACCGGC 
HOL2F 
SANK73390 
CGAGGGACCGGTAGTGAGTA
AAGAAGCTG  
Clone 
the 
HOL2 
fragment 
into 
pGEM-
T-easy 
AgeI-AvrII 
HOL2R 
CGCCCTAGGGCTATGCCCACT
AAGTTGG  
HOL3F 
SANK73390 
CCGCCTAGGTTGGTTTTCACA
ATAAC  
Clone 
the 
HOL3 
fragment 
into 
pGEM-
T-easy 
AvrII-BstbI 
HOL3R 
GCGTTCGAACTATGGCCCTTT
TGTCTTAGTAG  
tmlUHF 
SANK73390 
GGAGAGCTCATGAATGAGTC
AGCCCTTAACCC 
Clone 
couL 
into 
pJH10 
MfeI- XbaI 
tmlUHR 
GGCTCTAGATCATGACTCCAG
TACAGTTTGC 
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Table 2.10 Primers used in Chapter 6 
Name 
Template 
DNA 
Sequence Purpose 
Restriction 
sites 
KS2/KS1F 
(arm1) 
P. 
fluorescens10
586 
CGCAAGCTTCATATGCGCGA
CCAGGACATCGTGGTCGAG
CCAGCGGTACTGTTCGAGCA
CGCTAC 
Replacing 
KS2 loop 
with the 
KS1 loop 
HindIII 
EcoRI- 
KS2/KS1
R (arm1) 
CATACTGGCCGCCTGGTCCA
GCCCTTCGCCGGGATCAATC
TGGGCCTGGAGTAGGTTGA
GGTGGTATTCGTTACGCTCG
GCGGCCACGAATACGCCGA
CCTTCTCC 
KS2/KS1F 
(arm2) 
CTGGACCAGGCGGCCAGTA
TGATCGCCAACCGCGTGTCT
TATC 
KS2/KS1
R (arm2) 
GGCGAATTCGATGGGATCG
CCCAGCGCCGTAC 
KS2/KS3F 
(arm1) 
P. 
fluorescens10
586 
CGCAAGCTTCATATGCGCG
ACCAGGACATCGTGGTCGA
GCCAGCGGTACTGTTCGAGC
ACGCTACGCC 
Replacing 
KS2 loop 
with the 
KS3 loop 
HindIII 
EcoRI- 
KS2/KS3
R (arm1) 
CGACGATGGGCTCATGGAC
AGCACCAGCGGCCGCCCCT
CGGCAGTCTGTTGCGCCCCA
TACAGTTGGTACTCTTCGTA
CGTTACGCCCACGAATACGC
CGACCTTCTCC 
KS2/KS3
R (arm2) 
GCTGTCCATGAGCCCATCGT
CGATCGCCAACCGCGTGTCT
TATC 
KS2/KS3
R (arm2) 
GGCGAATTCGATGGGATCG
CCCAGCGCCGTAC 
tmlUHR 
GGCTCTAGATCATGACTCCA
GTACAGTTTGC 
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2.2.1 Velocity DNA polymerase kit 
Velocity polymerase possesses 3´-5´ proofreading exonuclease activity which 
makes it suitable for high fidelity PCR. Velocity DNA has been developed to reduce 
extension time remarkably to 10s/kb, as opposed to 2 minutes for Taq polymerase. Also, 
velocity polymerase can be used to amplify fragments as large as 9kb from genomic DNA 
with high yield due to its processivity. Details of the reaction mixture are outlined in Table 
2.11.  A Sensoquest labcycler was used to carry out PCR using the program in Table 2.12. 
Table 2.11 Velocity DNA polymerase reaction conditions 
Reagents  Volume/Reaction µl 
5x Hi-Fi reaction buffer (contains 10 mM 
Mg+2) 
10 
dNTPs (2.5 mM) 5 
Forward primer (10 µM) 2 
Reverse primer (10 µM) 2 
DMSO 1.5 
ddH2O 27.7 
Velocity DNA polymerase 0.5 
 
Table 2.12 Velocity PCR program details 
Description  Length  Temp (C°) Cycles  
Initial 
denaturation  
2.00 min 98 1 
Denaturation  30 sec  98 
25-35 Annealing  30 sec 50-68  
Extension  15-30s/kb 72 
Final 
extension  
4-10 min 72 1 
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2.2.2 Invitrogen Taq polymerase 
Taq DNA polymerase is isolated from Thermus aquaticus. It is a heat stable 
enzyme but it does not have a 3-5 exonuclease activity and consequently no proofreading 
function. For this reason, Taq was only used for PCR screening following the protocol 
detailed in Table 2.13. PCR conditions are listed in Table 2.14 
Table 2.13 Taq DNA polymerase reaction conditions 
Reagents  Volume/Reaction µl 
10x Buffer DNA 5 
dNTPs (2.5 mM) 4 
Forward primer (100 µM) 0.3 
Reverse primer (100 µM) 0.3 
50% glycerol  1.5 
ddH2O 27.8 
MgCL (50mM) 1 
Taq DNA polymerase 0.6 
 
Table 2.14 PCR program for Taq DNA polymerase 
Description  Length  Temp (C°) Cycles  
Initial 
denaturation  
2.00 min 94 1 
Denaturation  15 sec  94 
30 
Annealing  30 sec (Tm — 4) 
Extension  1.00 min  72 
Final 
extension  
7.00 min 72 1 
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2.2.3 QuickChange site directed mutagenesis  
For site directed mutagenesis; the QuikChange Lightning Multi Site-Directed 
Mutagenesis Kit from Agilent Technologies was used, and amplification of the mutated 
fragments was done according to the manufacturer’s protocol. The desired point mutation was 
designed to be close to the middle of the primer with ~10–15 bases of template-complementary 
sequence on both sides. Details of the protocol and PCR conditions are shown in Table 2.15 and 
Table 2.16 respectively. 
Table 2.15 QuickChange site directed mutagenesis reaction conditions 
Reagents  Volume/Reaction µl 
10x Buffer DNA 5 
dNTPs (2.5 mM) 1 
Forward primer (10 µM) 1 
Reverse primer (10 µM) 1 
QuickSolution reagent  1.5 
ddH2O To a final volume of 50 
DsDNA template  10-100 ng 
 
Table 2.16 PCR parameters for the QuickChange Lightning Site-Directed Mutagenesis  
Segment   Length  Temp (C°) Cycles  
1  2.00 min 95 1 
2 
20 sec  95 
18 10 sec 60 
30 sec /kb 68 
3 5.00 min 68 1 
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2.3 DNA manipulation 
2.3.1 Plasmid extraction  
Plasmid extraction was performed using Bioneer Accuprep® plasmid mini 
extraction kit or ISOLATEII plasmid mini kit from Bioline. 
2.3.1.1 ISOLATEII plasmid mini kit from Bioline 
Plasmid isolation was carried out using the solution provided by Bioline and 
according to the manufacturer’s protocol. E. coli LB culture, 5ml, was harvested by 
centrifugation for 2 min at 11,000xg. The supernatant was then discarded and 500µl of the 
Buffer P1 was added to the pellet which was then resuspended by vortexing or pipetting up 
and down. The cells were lysed by adding Buffer P2 and gently inverting the tubes 6-8 
times to avoid shearing of genomic DNA. The mix was incubated at room temperature for 
5 min or until the lysate appears clear. 600µl of the neutralization buffer P3 was added and 
the tube was again thoroughly mixed by inverting. To clarify the lysate cells were spun for 
10 minutes at 11,000 xg at room temperature. Binding of the DNA was achieved by 
pipetting 750µl of the clear lysate into ISOLATEII plasmid mini spin column and 
centrifuged for 1 minute at 11,000 x g. The flow-through was discarded and 500µl of wash 
buffer PW1 (preheated to 50°C) was added to the filter and centrifuged for 1 minute at 
11,000 xg/11336.52 rpm 600µl of washing buffer PW2 was also added to the filter and 
centrifuged for 1 minute at 11,000 xg. After discarding the flow-through, the sample was 
centrifuged for another 2 minutes to remove residual ethanol. To elute, the spin column 
was placed in a 1.5 ml microcentrifuge tube and 50µl buffer P (preheated to 70°C) was 
directly added to the centre of the silica membrane and incubated for 2 minutes before it 
was spun down for 1 minute at 11,000 xg. 
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2.3.1.2 Bioneer Accuprep® plasmid mini extraction kit 
5 ml of E. coli LB culture was collected by centrifugation at >8,000 rpm for 2 
minutes. The supernatant was completely removed by pipetting and the cells were 
resuspended in 250 µl of Buffer 1. 250µl of buffer 2 was added to the previous mix. In 
order to get a clear lysate, 350µl of buffer 3 was added and the tubes were gently inverted 
3-4 times to thoroughly mix the contents. The samples were then centrifuged at 16,600 x g 
at 4°C for 10 min or until white protein aggregation could be seen on the bottom of the 
tube leaving a clear lysate. Plasmid purification process involved transferring the cleared 
lysate to the DNA binding column, centrifugation at 16,600 x g for 1 minute and adding 
500µl of buffer D (incubation for 5 minutes) the purpose of which is to inactivate any 
endonucleases that might degrade the plasmid DNA. To remove salts and other soluble 
debris, 700µl of buffer 4 was added to the DNA binding column and centrifuged for 1 
minute at 16,600 x g. The flow-through was discarded and the samples were centrifuged 
again for 1 minute at 16,600 x g to remove any residual ethanol. The DNA binding column 
was transferred into a new microcentrifuge tube and DNA was eluted by adding 50 - 100µl 
of buffer 5 to the DNA binding filter.  This was incubated for 1 minute and then 
centrifuged for 1 minute at 16,600 x g. 
2.3.2 Restriction digest  
Restriction digestion was carried out using enzymes purchased from New 
England Biolabs (NEB). Reaction volume was 50 µl for the purpose of cloning and 20µl 
for insert detection. The amount of enzymes added to the reaction did not exceed 2 µl. 4-
5µl of the (10x) appropriate buffer was added which also includes the Bovine serum 
albumin (BSA).  5 -30µl of DNA was added to the reaction and the final volume was made 
up by adding sterile distilled H2O. The samples were incubated at 37°C for two hours.   
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2.3.3 Agarose gel electrophoresis 
Gels with a concentration of 1% (w/v) agarose were used to analyse PCR and 
restriction digest products. Agarose (1g) was suspended in 100ml of TAE buffer (40mM 
tris-acetate, 1mM EDTA pH8.0). The mixture was microwaved for 2 minutes and then 
cooled down at room temperature before adding 2µl of ethidium bromide solution (10mg 
ml-1). The gel was poured into a tray, combs were inserted and then the gel allowed to set 
at room temperature. DNA samples to be loaded were prepared by adding 2µl of loading 
buffer (bottom: 0.25% w/v bromophenol blue, 15% w/v ficoll; top: 0.25% w/v xylene 
cyanol, 15% w/v ficoll) to 5µl DNA and 5µl H2O. The samples were run on a gel 
alongside 1kb DNA molecular ladder (Fermentas) at 100V/500mA for 40 minutes. DNA 
was then visualised using a UV transilluminator.  
2.3.4 DNA extraction from TAE (Tris-acetate-EDTA) agarose gel 
Extracting DNA samples from agarose gel was carried out using the Illustra GFX PCR 
DNA and gel band purification kit from GE healthcare. The purification procedure was performed 
according to GE healthcare instructions with the solutions provided by the manufacturer. After the 
DNA samples were cut out of the agarose gel, gel bands were weighed and placed in a 1.5 ml 
microcentrifuge tube and capture buffer 3 was added (10µl/10mg). Samples were incubated in a 
55°C water bath and inverted every 3 minutes until the gel bands were completely dissolved.  Up 
to 800µl of capture buffer 3 was transferred to the GFX microspin column, incubated at room 
temperature for 1 minute and then centrifuged at 16,000x g for 30 seconds. The flow-through was 
removed and the filter was washed by adding 500µl of wash buffer type 1 to the GFX microspin 
column and centrifuging at 16,000x g for 30 seconds. The GFX microspin column was then 
transferred to a new 1.5 ml microcentrifuge tube and DNA was eluted by adding 10-50 µl elution 
buffer type 4, incubating for 1 minute at room temperature and spinning the samples at 16,000x g 
for 1 minute to recover the purified DNA. The purified DNA samples were stored at -20 oC 
degrees. 
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2.3.5 A-tailing blunt-ended PCR products 
PCR products were A-tailed in order to ligate them to pGEM-T-Easy, a linearized 
vector with a single 3ʹ-terminal thymidine at both ends which makes it necessary to add an 
A tail to the insert.  The components detailed in Table 2.17 were all mixed in a 
microcentrifuge tube and incubated at 70°C for 30 minute prior to ligation to pGEM-T-
Easy. 
 
 
Table 2.17 A-tailing blunt ended PCR products 
Reagents  Volume/Reaction µl 
Purified PCR fragment 6 
Invitrogen Taq MgCl2 1 
dATP (2mM) 1 
10 x Invitrogen Taq buffer  1 
Invitrogen Taq DNA polymerase  1 
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2.3.6 DNA ligation 
Ligations were performed either by using pGEM-T-Easy vector system which 
provides the blue/white screening option for inserts, or using the T4 DNA ligase kit from 
(Invitrogen). The DNA concentration of both the vector and the insert were determined 
using a Nano-drop machine (ND-100) or run on an agarose gel alongside known quantities 
of molecular weight standards. The following method was used to calculate 3:1 ratio for 
ligation reactions:  
Ratio unit = 
𝑠𝑖𝑧𝑒 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟
𝑠𝑖𝑧𝑒 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡
  
Ratio factor = 
3
𝑟𝑎𝑡𝑖𝑜 𝑢𝑛𝑖𝑡
 
Molecular weight in ng of vector and insert required for the ligation 
50ng (vector) x ratio factor = ng of insert 
Ligation reactions were usually made up in 20µl volume and incubated overnight at 4°C. 
 
2.3.7 Splicing by overlap extension (gene SOEing) 
SOEing PCR was used to introduce site specific mutations, deletions or generating 
recombinant gene constructs.  This was achieved by designing specific primers that include in their 
sequence the desired changes and also have terminal complementarity; two overlapping fragments 
can be attached together by a subsequent extension reaction (Figure 2.1). This method can be 
applied to fuse together two or more DNA fragments from different genes to produce the desired 
recombinant.  
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Figure 2.1 Splicing by overlap extension.  Fragment AB is amplified using primers A 
and B, while fragment CD is amplified using primers C and D. For site directed 
mutagenesis pieces AB and CD are adjacent parts of the same gene where the mutation 
will be introduced. Primers B and C are chimeric, and are designed in a way that that the 
3’ ends complement fragment AB and fragment CD respectively. The PCR products (AB 
and CD) are gel purified and mixed together with all the required PCR components except 
the primers. AB and CD act as primers in this situation and allow the DNA to extend using 
the sequence complementarity between the two DNA pieces. A final PCR is carried out, 
this time with the primers A and D to produce the recombinant product.  
 
  
Recombinant product 
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2.3.8 DNA transformation  
E. coli competent cells of S17-1 and DH5α were made according to (Cohen et al., 
1972). An overnight culture of E. coli was diluted 1:100 in fresh L broth and grown at 
37°C, 200 rpm until the OD600 reached 0.4-0.6. The cells were centrifuged at 11,000xg, 7 
minutes and 4°C. The supernatant was removed and the cells resuspended in pre-chilled 
100mM CaCl2 (2ml per 5ml of culture). Cells were incubated on ice for 20 minutes, spun 
down for another 7 minutes at 4°C and 11,000xg. The supernatant was discarded and the 
pellet was resuspended in pre-chilled 100 mM CaCl2 (0.5 ml per 5ml culture). At this stage 
the cells should be competent but were left on ice for several hours to improve their 
competency. Competent cells were stored at 4°C for up to two weeks. Transformation was 
achieved by adding 5µl of DNA to 100µl of competent cells. The mixture was left on ice 
for 30 minutes after which the cells were heat shocked by placing them in a 42°C water 
bath for 2 minutes. 1ml of L broth was added and the tubes were incubated at 37°C, 200 
rpm for 1 hour. Cells were then plated out on selective plates and incubated overnight at 
37°C. 
2.3.9 DNA sequencing  
For the clone to be sequenced, plasmid DNA was first extracted, of which 200-
500ng was added to 3-4pmoles of the appropriate primers and the volume made up to 10µl 
with sterile distilled H2O. Sequencing services were provided by the functional genomics 
laboratory at the University of Birmingham using an ABI 3700 analyser. Chromas Lite 
was used to analyse the generated sequences. 
2.3.10 Sequencing analysis 
Alignments of DNA and amino acid sequences were performed using the BLAST 
function (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Alignments for multiple amino acid and 
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protein sequences were generated using COBALT 
(http://www.ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi) or ClustalW 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/).  
2.3.11 Conjugation and suicide vector excision  
Conjugation was used to mobilize expression vectors and suicide plasmid 
derivatives from E. coli S17-1 to P. fluorescens. The process starts with mixing 1 ml of E. 
coli S17-1 containing the desired plasmid with 1 ml of P. fluorescens. The bacterial mating 
mixture was then collected by filtering onto a sterile 0.45µM Millipore filter which was 
then placed on an L agar plate at 30°C and left overnight to allow conjugation.  The filter 
was washed with 1 ml sterile saline solution (0.85%) and serial dilutions were made 
ranging from 10-1 to 10-5. 100µl aliquots from each dilution was plated on selective plates 
or M9 minimal media: 200ml salt solution containing NA2HPO4 (6g/l), KH2PO4(3g/l), 
NH4Cl (1g/l),MgSO4(1mM), thiamine HCl (1mM), CaCl2(0.1mM),glucose (0.2%) added 
to 200ml 50% H2O agar) and left for 2-3 days to grow at 30°C. In the case of M9 minimal 
medium, single colonies were restreaked on selective M9 plates and incubated at 30°C for 
2-3 days. Single colonies of the transconjugants were then streaked on selective L agar 
plates, while for chromosomal integration purposes the plates were supplemented with 
kanamycin.  Overnight cultures were made out of the co-integrant colonies; serial dilutions 
were made and plated on L agar with 5% (w/v) sucrose to select for bacteria in which the 
integrated suicide vector has excised and been lost. To check for integration, colonies were 
patched onto an ampicillin plate followed by a kanamycin plate simultaneously and then 
incubated at 30°C for 2 days. Colonies were screened for the correct genotype by colony 
PCR. 
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2.4 Bioassay for Mupirocin production 
The OD600 of overnight cultures of both wild type and mutant P. fluorescens was 
measured and the cultures were diluted to the OD600 of the least dense culture. Culture 
(10µl) was spotted on 20ml L agar plates which were incubated at 30°C overnight. The 
spots were then over-laid with L agar containing 40µl ml-1 B. subtillis overnight cultures 
and 2,3,5-triphenyltetrazolium chloride TTC (0.25mg ml-1) and incubated overnight at 
37°C. TTC is a commonly used redox indicator to signify cellular respiration since it acts 
as an alternative electron acceptor. Therefore, the agar turns red due to the actively 
growing B. subtillis, while where there is no growth the agar remains colourless. 
Mupirocin production was estimated by measuring the clearing zone where B. subtillis did 
not grow. Assays were done in triplicate and analysed statistically by calculating standard 
errors. 
2.5 Bacterial two hybrid system 
The bacterial two hybrid system (BACTH) exploits the fact that the catalytic domain of 
adenylate cyclase (CyaA) from Bordetella pertussis consists of two complementary 
fragments, T25 and T18, (Figure 2.2) that are not active when physically separated. When 
these two fragments are fused to interacting polypeptides, X and Y, heterodimerization of 
these hybrid proteins results in functional complementation between T25 and T18 
fragments and therefore cAMP synthesis. Cyclic AMP produced by the reconstituted 
chimeric enzyme binds to the catabolite activator protein, CAP. The cAMP/CAP complex 
is a regulator of gene transcription in E. coli and it is involved in turning on the gene 
expression of, for example, the lac and mal operons involved in lactose and maltose 
catabolism. As a result, bacteria become able to utilize lactose or maltose as the unique 
carbon source and can be easily distinguished on indicator media. As a positive control, 
the reporter strain BTH101 were co-transformed with pUT18-zip and pKT25-zip while the 
77 
 
negative control was BTH101 transformed with the empty vectors pUT18 and pKT25 
(Battesti and Bouveret, 2012). The genes encoding the proteins of interest were amplified 
by PCR and cloned into the vectors PKT25 and pUT18 in frame with the T25 and T18 
fragments. The constructs were then transferred into DH5α strain and the plasmid DNA 
purified as described in section 2.3.1.  The reporter cell BTH101 strain was then co-
transformed with the two recombinant plasmids and incubated on indicator plates 
containing X-Gal (40 µg/ml) and 0.5 mM IPTG at 30°C for 24-72 hours.  
 
Figure 2.2 Principle of bacterial two hybrid system (Battesti and Bouveret, 2012). A) 
When the T25 and T18 fragments are co-localised they catalyse cAMP synthesis. B) When 
not co-localised, the fragments do not catalyse cAMP synthesis. C) When the T25 and T18 
tags are fused to proteins that interact, the interaction can be detected by the co-localisation 
of T25 and T18 and the subsequent cAMP synthesis. D) Increased cAMP concentration 
leads to increased binding of cAMP to CAP, which is a regulator of several reporter genes. 
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2.6 High performance liquid chromatography 
2.6.1 Mupirocin detection 
Seed cultures of the tested strains were prepared by inoculating one colony into 
25ml LB in a 250ml flask and incubating at 25°C and 200 rpm for 16 hours.  25ml of SSM 
medium (25g.L-1, soya flour, 2.5 spray dried corn liquor, 5 (NH4)2, 0.5 MgSO4.7H2O, 1 
Na2HPO4, 1.5KH2PO4, 1 KCL, 6.25 CaCO3, 4% Glucose) was inoculated with 1.25ml of 
the seed culture and incubated at 22°C, 200 rpm for approximately 40 hours. Samples were 
then centrifuged at 29,000xg for 10 minutes and the supernatant pH was adjusted to 4.5 
with HCL. Prior to running the samples, supernatants were filtered using 0.2µm filters. 
HPLC was performed on a Gilson system using a reverse phase C18 column (15cm x 
4.6mm) with a mobile phase of water/acetonitrile gradient (5-70% acetonitrile 
trifuoroacetic acid (0.01%)) over 60min at 1ml min-1 flow rate.  Compounds were detected 
by UV absorption at 233nm and data was analysed using Unipoint LC system software. 
2.6.2 Thiomarinol detection 
Thiomarinol was extracted from 2ml SANK73390 culture. The culture pH was 
adjusted to pH6 and an equal volume of acetone was added to each culture.  The mixture 
was vortexed for about 5 minutes and left for at least an hour at 4°C. The acetone was then 
removed using a speed vacuum pump for approximately 1 hour prior to adding an equal 
volume of ethyl acetate.  The mix was left to settle until it had separated into two clear 
phases, the yellow layer at the top containing Thiomarinol and ethyl acetate and the bottom 
layer containing all the cell debris. The upper phase was transferred into a 2 ml 
microcentrifuge tube and the ethyl acetate was completely removed by the speed vacuum 
pump after which Thiomarinol was resuspended in 200µl methanol and analysed by HPLC 
with UV detection at 385nm. 
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2.7 β-galactosidase assay 
Bacterial cells to be tested for their β-galactosidase activity were grown in 5 ml of 
LB broth in the presence of 0.5 mM IPTG and appropriate antibiotic at 30°C and 200 rpm 
for 4-6 hours or overnight. The cultures were then diluted 1-5 with 1x M63 medium which 
was prepared from autoclaved x5 M63 (10 g (NH4)2SO4, 68 gKH2PO4, 2.5 mg 
FeSO4.7H2O, 5 mg vitamin B1, and deionized H2O to a final volume of 1 L, pH adjusted 
to 7.0 with KOH) and the OD600 was measured. For the purpose of permeablizing bacterial 
cells 30µl of both toluene and 0.1% SDS solution were added to 2.5 ml of the diluted cell 
suspension. The cells were vortexed for 10 seconds and left at 37°C for 30-40 minutes to 
allow the toluene to evaporate.  In a test tube 100 µl of the permealized cells were added to 
900 µl of PM2 buffer (70 mM Na2HPO4.12H20, 30 mM NaH2PO4 H20, 1 mM MgSO4,0.2 
mM MnSO4, pH 7.0, plus 100mM of β-mercaptoethanol added just before use) the tubes 
were then left in a 28°C water bath for 5 minutes. 
To start the enzymatic reaction 250 µl of the ONPG substrate solution (0.4% 
ONPG in PM2 buffer without the β-mercaptoethanol) preheated to 30°C was added to the 
previous mix of permeablized cells and PM2 buffer. The reaction was stopped after 10 
minutes by adding 500 µl of 1M of Na2CO3. The OD420 was measured and the enzymatic 
activity was calculated based on the following equation: A (units/ml) = 200 x (OD420 – 
OD420 in control tube) / min of incubation) x dilution factor. 
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3 The effect of the amide synthetases NovL, CloL, CouL and SimL on 
production of pseudomonic acids 
 
3.1 Introduction  
The concept of mutasynthesis was first introduced by Birch (1963) as a way to 
generate analogues of different antibiotics from different classes, by utilizing genetically 
modified organisms in combination with feeding of chemical precursors. However, the 
term itself was coined by Rinehart in 1977 (Rinehart, 1977). Although very similar to the 
precursor directed biosynthesis (PDB), the mutasynthesis approach was able to eliminate 
competing natural precursors. Therefore, a less complex mixture of metabolites is 
produced, which makes purification of compounds simpler, yields higher and also 
increases the chances of successful incorporation of more diverse precursor analogues 
(Kennedy, 2008). 
Mutasynthesis initially involved random mutagenesis, which was then followed by 
isolation and characterisation of the non-producing strains. One of the first mutasynthesis 
studies was conducted using the strain Streptomyces fradiae that produces neomycin B2 
(Shier et al., 1969). The strain was subjected to random mutagenesis, which resulted in 
mutants that can only produce neomycin B2 when supplemented with the aminocyclitol 
precursor deoxystreptamine. When this mutant strain was supplemented with the 
aminocyclitols streptamine and epistreptamine, these unnatural precursors were utilised by 
the biosynthetic machinery to produce the novel neomycin analogues, hybrimycin A1 6 
and hybrimycin B2 7 respectively (Kennedy, 2008). 
 Following the successful generation of neomycin analogues, this method was 
applied to many different biosynthetic pathways in order to create a wide range of 
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analogues, which included macrolide antibiotics such as erythromycin and platenolides in 
addition to β-lactams antibiotics (Daum and Lemke, 1979). Combinatorial biosynthesis 
was also amongst the approaches developed to achieve diversity in natural products. This 
technique combines genes from different biosynthetic pathways in order to generate novel 
compounds. In this respect, the aminocoumarins have been the perfect example of creating 
new structural variants through utilizing synthetic chemistry and genetic engineering 
(Heide, 2009b) (Figure 3.1). 
 
 
Figure 3.1 Aminocoumarin antibiotics and the biosynthesis of novobiocin (reproduced 
from Anderle et al., 2007b). 
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A prenyalated 4-hydroxybenzoyl moiety is the starter molecule in the clorobiocin 
biosynthetic pathway. It is formed from 4-hydroxyphenylpyruvate and dimethylallyl 
diphosphate and catalyzed by CloQ and CloR. Studies in the Lutz Heide lab confirmed that 
inactivation of either CloQ or CloR abolishes prenyalated 4-hydroxybenzoyl production 
and consequently antibiotic production (Pojer et al., 2003). To overcome this hurdle, 
synthetic analogues of the 4-hydroxybenzoyl moiety were added to the mutant strain 
lacking CloQ/ CloR, which resulted in formation of different clorobiocin analogues. This 
demonstrated the successful incorporation of these synthetic analogues into the clorobiocin 
skeleton. Although this was a very encouraging finding, substrate specificity appeared to 
prevent efficient incorporation of the synthetic substrate analogue (Heide, 2009b). This 
was overcome by using amide synthetases from other aminocoumarin pathways to replace 
CloL, and test their specificity in accepting different precursors. In the case of clorobiocin, 
it was found that the amide synthetase SimL and CouL from coumermycin and 
simocyclinone clusters respectively, were the most promiscuous in accepting a variety of 
precursors which were not accepted by CloL (Anderle et al., 2007b, Heide, 2009b).   
NovL, CloL, CouL and SimL are all amide ligases essential for the assembly of 
novobiocin, clorobiocin, coumermycin and simocyclinone, respectively. Whereas TmlU is 
a CoA - ligase in the Thiomarinol biosynthesis cluster (see section 1.3.7), and together 
with HolE, has been demonstrated responsible for catalysing the attachment of the 
marinolic acid part to the holomycin part of the pathway (Figure 1.17) (Dunn et al., 2015). 
Given the role they play in their native systems, these enzymes might be able to act as a 
linking agent between two molecules from different pathways. 
 In this chapter we aimed to develop a combinatorial biosynthesis and 
mutasynthesis-based approach for the development of new bioactive molecules centered 
on the Mupirocin, Thiomarinol and Aminocoumarins. We aimed to test the hypothesis – 
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can TmlU, SimL and their homologues catalyse the linkage of mupirocin to other 
compounds, initially thiomarinol and aminocoumarin.  
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3.2 Results  
3.2.1 Constructing pSIML, pCLOL, pNOVL and pCOUL 
The genes simL, cloL, novL and couL from Streptomyces species were cloned into 
the broad host expression vector pJH10 using the primers listed in (Table 2.7). PCR 
products for simL and novL were digested with EcoRI and XbaI, while cloL and couL were 
digested with MfeI (which recognises CvAATTG and produces sticky ends identical to 
those produced by EcoRI) and XbaI. All were inserted into the expression vector pJH10 
digested with EcoRI and XbaI. The resulting plasmids were designated pSIML, pCLOL, 
pNOVL and pCOUL, and only the sequenced clones were used in the downstream 
applications. 
 
Figure 3.2 Cloning simL, novL, couL and cloL.  The map of the vector pJH10 showing 
the insertion of simL (red arc), novL (blue arc), couL (green arc) and cloL (magenta arc). 
pSIML (15.26kb), pCLOL (15.27kb), pCOUL (15.27kb) and pNOVL (15.30kb). 
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3.2.2 HPLC analysis of pseudomonic acids produced by P. fluorescens WT 
NCIMB10586, NCIMB10586 (pSIML), NCIMB10586 (pNOVL), 
NCIMB10586 (pCLOL), NCIMB10586 (pCOUL) 
Following the method described in section (2.6.1), pseudomonic acids produced 
were detected using HPLC for P. fluorescens NCIMB10586 with each of the amide 
synthetases expressed in-trans. NCIMB10586 WT and NCIMB10586-pJH10 were used as 
controls, and all the samples were tested in biological triplicates. Unlike when TmlU (the 
CoA-ligase in the thiomarinol biosynthesis cluster which interfered with mupirocin 
biosynthesis) was introduced, mupirocin was still produced. No significant difference in 
pseudomonic acid A production was observed with expression of each homolog in-trans 
(Figure 3.3), integration of peaks is recorded in Appendix A. 
As these homologues were not inhibitory to mupirocin biosynthesis like TmlU, 
they proved good candidates for mutasynthetic experiments. 
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Figure 3.3 HPLC chromatograms  of NCIMB10586 WT, NCIMB10586 pJH10, 100μM 
pseudomonic acid A standard, NCIMB10586 pSIML, NCIMB10586 pNOVL, 
NCIMB10586 pCLOL and NCIMB10586 pCOUL. UV of (233nm). 
 
P. fluorescens WT P. fluorescens pJH10 
PA-A 
PA-A 
P. fluorescens pNOVL 
PA-A 
PA-A 
P. fluorescens pCOUL P. fluorescens pCLOL 
PA-A 
PA-A 
PA-A standard (100μM) 
PA-A 
P. fluorescens pSIML 
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3.2.3 Effect of the amide synthetases on thiomarinol production and attempts to 
complement a ΔtmlU mutant 
When tmlU (section 1.3.7) was deleted in pTML1 (thiomarinol cluster), marinolic 
acid and pyrrothine were produced separately, implying that TmlU plays a role in 
attaching these two parts together (Fukuda et al., 2011). In the aminocoumarin system 
several amide synthetases play a similar role, these include SimL, CloL, CouL and NovL 
(section 1.4).  The aims of this experiment were to investigate whether it is possible to 
complement Pseudoalteromonas spp. SANK73390ΔtmlU with tmlU expressed in trans, 
and furthermore whether the amide ligases from the aminocoumarin pathways 
complement. The outcome of this study should be beneficial in deciding to what extent 
these amide synthetases can be exploited to make hybrid biosynthetic pathways. 
 
 
 
Figure 3.4 HPLC chromatograms of tmlU complementation experiment.   tmlU was 
expressed in trans in ΔtmlUSANK73390. The green line represents the mobile phase 
  
ΔtmlU-SANK 73390pAMHI SANK 73390 WT 
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For this purpose, the amide synthetases were expressed in trans in 
SANK73390ΔtmlU. SANK73390 WT and SANK73390ΔtmlU were used as controls. 
thiomarinol was extracted from the transconjugant SANK73390 strains as described in 
(section 2.6.2) and detection of thiomarinol plus any new products was carried out by 
HPLC. Expression of tmlU in-trans from pJH10-tmlU in SANK73390ΔtmlU did not 
restore thiomarinol production (Figure 3.4). No complementation was observed for SimL, 
NovL, CloL or CouL as well (data not shown).  
Introducing SimL, NovL, CloL and CouL to a wild type SANK73390 did not 
have any effect on Thiomarinol production and a clear peak of Thiomarinol was observed 
at a retention time of 10 minutes (Figure 3.5). As these aminocoumarin amide synthetases 
had no detectable inhibitory effect on both mupirocin and thiomarinol production, they 
showed potential for mutasynthetic feeding experiments. 
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Figure 3.5 HPLC chromatograms showing the effect of simL, novL, cloL and couL on 
thiomarinol production.  Production cultures and HPLC analysis was performed in 
triplicate, and integrated peak areas are listed in Appendix A. 
SANK 73390pNOVL SANK 73390pSIML 
SANK 73390pCLOL SANK 73390pCOUL 
SANK 73390 WT 
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3.2.4 Feeding studies  
Of the substrates for these four amide ligases, those for SimL can arguably be 
regarded as the most similar to those for TmlU, since they can be divided into a fatty acid 
chain on one side and the aminocoumarin moiety on the other (Figure 3.6). There are 
similarities to the 8-hydroxyoctanoic acid in the thiomarinol pathway and the 9-
hydroxynonanoic acid in mupirocin pathway. This similarity led us to design an 
experiment in which aminocoumarin is fed to P. fluorescens NCIMB10586 expressing 
SimL and see whether SimL can catalyse the joining of the aminocourmarin to the 
pseudomonic acid. For the same purpose the other amide synthetases NovL, CloL, CouL 
were tested. 
 
Figure 3.6 The structural similarities between mupirocin, thiomarinol and 
simocyclinone. The fatty acid chain is underlined in red (Gurney and Thomas, 2011) 
(Pacholec et al., 2005). 
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In order to investigate how SimL, NovL, CloL and CouL could assist in the 
process of creating a hybrid compound, different concentrations of aminocoumarin-3 were 
fed to P. fluorescens with each of the amide ligases genes expressed in trans. 
Aminocoumarin was dissolved in DMSO, filtered-sterilised, and fed to the fermentation 
media at the same time as inoculation. Aminocoumarin concentrations ranged from 
10µg/ml to 2560µg/ml, each concentration was repeated in triplicate. The culture was then 
incubated at 22 ºC and 200 rpm for 48 hours. The cells were separated from the media by 
centrifugation 11000 xg for 10 minutes, and the supernatant analysed by HPLC. P. 
fluorescens pSIML was fed with aminocoumarin in the concentration range 10-160 µg/ml. 
PA-A production started to decline with >80µg/ml aminocoumarin until it was completely 
abolished at 320µg/ml (Figure 3.7). No new compounds were observed at any of the 
concentrations (Figure 3.8). 
P. fluorescens (pNOVL), P. fluorescens (pCLOL) and P. fluorescens (pCOUL) 
were fed with aminocoumarin at concentrations 20, 40 and 80 µg/ml, which also did not 
result in any noticeable new products, (Figure 3.8). IPTG induction did not show any 
additional evidence for incorporation (data not shown). 
 
 
 
Figure 3.7 HPLC chromatograms for feeding P. fluorescens WT with 320 µg/ml of 
aminocoumarin. 
P. fluorescens WT+320µg/ml  
P. fluorescens WT 
Aminocoumarin 320 µg/ml 
 
 
PA-A 
Aminocoumarin 
Aminocoumarin 
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Figure 3.8 HPLC chromatograms of P. fluorescens expressing different amide ligases 
with feeding of aminocoumarin. The RED line represents 230 µg/ml of aminocoumarin 
as a control; the BLUE line represents P. fluorescens WT, while the YELLOW line 
represents P. fluorscens with the chosen amide ligase expressed in trans. Integration of 
peak areas is presented in Figure 3.9. 
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Figure 3.9 Quantitative analysis of the aminocoumarin effect on PA-A production. 
Production cultures and HPLC analysis were performed in triplicate. Error bars represent 
the standard error of the mean. 
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3.2.5 Discussion  
Studies conducted on SimL so far showed that it is flexible in terms of accepting 
precursors (Luft et al., 2005). It was found that in addition to its natural substrate 
simocyclinone C4, SimL would accept a number of cinnamic and benzoic acid derivatives 
(Luft et al., 2005). These findings make SimL and other aminocoumarin amide ligases 
very attractive tools for creating new hybrid compounds with potential antibacterial 
activity. As such this part of the project was designed to investigate the possibility of 
creating new products derived from the pseudomonic acid or pyrrothine moieties of 
mupirocin or thiomarinol with antimicrobial activity. 
No significant inhibition of mupirocin or thiomarinol production was observed 
with in-trans expression of the aminocoumarin amide synthetases (sections 3.2.2 and 
3.2.3). This allowed them to be suitable candidates for the creation of hybrid compounds 
based on mupirocin and thiomarinol, potentially linking molecules from the different 
pathways such as pseudomonic acid and holomycin, as well as aminocoumarins. 
Especially since the latter compounds are a successful example of generating a hybrid 
antibiotic using mutasynthesis procedures (Anderle et al., 2007a). 
Whilst no restoration of thiomarinol production was observed in 
Pseudoalteromonas spp. SANK73390ΔtmlU expressing aminocoumarin amide synthetases 
in-trans, no complementation was also observed by pJH10tmlU. One potential explanation 
is that the mutation has had a polar effect on genes in the vicinity of tmlU, preventing 
complementation. Another explanation is that the level of expression of TmlU from pJH10 
is either too high or too low for complementation.  
HPLC analysis showed that adding aminocoumarin seems to decrease PA-A 
production, although no new compounds were detected. As the aminocoumarin 
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concentration was increased, the amount of PA-A produced was observed to decrease 
(Figures 3.8 and 3.9), with the exception where couL was expressed. Adding 
aminocoumarin to P. fluorescens (pCOUL) did not seem to affect PA-A production.  
Amongst the tested amide synthetases, SimL was the most promising due to its 
structural resemblance to both thiomarinol and mupirocin, (Figure 3.6). However, previous 
mutasynthetic approaches to create new compounds in aminocoumarins showed that 
although these amide synthetases come from the same class of antibiotics, they do not 
necessarily respond in the same way when it comes to accepting different substrates. This 
is evident when CloL, the amide synthetase of clorobiocin did not accept prenyalated 4-
hydroxybenzoyl analogues, while CouL, which shares 91% sequence identity with CloL, 
proved more flexible and accepted several precursors (Anderle et al., 2007a). Although 
SimL and CouL were the most accepting of different substrates in the studies carried out 
by the Heide group, this flexibility did not result in success being observed with the 
heterologous expression of these proteins when introduced to the mupirocin pathway 
studied here, where no new compounds were observed. 
When introduced to the Mupirocin pathway, TmlU abolished Mupirocin 
production (section 1.3.7). This effect is not seen in the rest of the amide synthetases. 
SimL on the other hand, though it does not interfere with Mupirocin production is certainly 
not able to capture the required intermediate, and use it as a substrate and facilitate the 
formation of a new analogue. There is recent biochemical evidence which indicated that 
TmlU does not act alone but needs HolE to complete the amidation process in the 
thiomarinol cluster (Dunn et al., 2015). A potential explanation why SimL, and possibly 
the rest of the amide ligases presented here, were not observed to incorporate new 
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substrates is because they need to pair up with another enzyme in order to complete their 
action. 
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Chapter 4 
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4 Investigating the inhibitory effect on of TmlU on Mupirocin 
biosynthesis 
 
4.1 Introduction  
TmlU has previously been identified as a putative amide ligase, an enzyme in the 
thiomarinol biosynthesis pathway responsible for creating the amide bond between the 
monic acid and the holomycin moiety (Fukuda et al., 2011, Murphy et al., 2011). It has 
been recently discovered that TmlU is not the only enzyme that is responsible for this 
amidation, but instead it works alongside another enzyme, HolE, which is an 
acyltranferase (Dunn et al., 2015). Nonetheless, TmlU is still an essential part of the 
thiomarinol biosynthesis process and could be of great potential for creating diverse hybrid 
compounds, and generating new families of antibiotics.  
Attempts to create hybrid antibiotics by incorporating a range of different 
substrates using a general approach called mutasynthesis have been encouraging. For 
example, feeding a range of substrates like anhydrornithine and anhydrolysine into P. 
fluorescens strains defective in holA resulted in production of a number of pseudomonic 
acid derivatives (Murphy et al., 2011). However, to further exploit TmlU and its potential 
in such studies, more research is needed to understand its substrate specificity, what other 
roles TmlU is involved in within thiomarinol biosynthesis, and possibly its action when 
introduced to other biosynthetic pathways. 
Previous studies on TmlU have demonstrated that expressing tmlU in-trans in P. 
fluorescens resulted in a reduced yield of  PA-A and accumulation of truncated C5 of PA-B 
(Omer-Bali, 2013). This implies that TmlU interferes with biosynthesis of 9-
Hydroxynonanoic acid.  
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As discussed in section 1.3.2.3, MmpB is believed to be responsible for the 
biosynthesis of 9-hydroxynonoic acid. However, to date there is no direct evidence that 
this is the case. In combination with the knowledge that MmpB is capable of functioning 
with only one ACP (Shields et al., 2010), there might be more to the process of creating 9-
hydroxynonanoic acid than what we currently understand regarding the iterative 
condensations. One hypothesis that was proposed by (Omer-Bali, 2013) was that TmlU 
targets the active site of one of the ACPs in MmpB. This is the first hypothesis to be 
addressed in this chapter, through investigation of the effect of expression of TmlU in-
trans in P. fluorescens NCIMB 10586 carrying point mutations and deletions to the three 
ACP domains of MmpB. Omer-Bali reported that deletion of either ACP5 or ACP7 with 
TmlU expression yielded the C5 version of pseudomonic acid B (Figure 4.2). However, 
with deletion of ACP6, a small peak of pseudomonic acid A was observed. This suggested 
that deleting ACP6 reduces the negative impact of TmlU on mupirocin production. 
However, after the Omer-Bali observation proved un-reproducible, it was necessary to 
explore alternative hypotheses.  
As truncation of the 9-HN was observed with TmlU expression (Figure 4.2), it 
may be possible that TmlU interacts with the thioesterase domain of MmpB, somehow 
causing premature release. Therefore, several further hypotheses are explored in this 
chapter, firstly is enzymatic activity of TmlU required for its inhibitory impact. This was 
investigated through point mutations to TmlU. Secondly, does TmlU interact with MmpB, 
and can any interaction be narrowed down to a specific domain on MmpB. This hypothesis 
was explored through deletions and point mutation of the thioesterase domain and bacterial 
two hybrid tests. 
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4.2 Results  
4.2.1 Expressing pAMHI in P. fluorescens 
Plasmid pAMHI was constructed by Ahmed Omer-Bali (2013) by cutting out 
tmlU from a pET28a derivative using EcoRI and SalI, and cloning it into the expression 
vector pJH10 between EcoRI and XhoI. The construct was verified by both colony PCR, 
restriction digests, and sequencing.  
 
Figure 4.1 Map of the tmlU expression vector pAMH1. The tmlU open reading frame 
was cloned into the expression vector pJH10 between the EcoRI and XhoI sites. 
 
  
tmlU 
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4.2.2 HPLC analysis of P. fluorescens-pAMHI (P. fluorescens NCIMB 10586 
strains expressing tmlU) 
To provide a base line for the impact of tmlU, HPLC analysis was performed on 
the wild type strain P. fluorescens NCIMB 10586 and strains with pJH10 expressing tmlU 
in-trans, to determine the impact on pseudomonic acid production. HPLC data revealed 
that both P. fluorescens NCIMB 10586 WT and P. fluorescens NCIMB 10586(pJH10) 
produced pseudomonic acid A and B. The C5 version of PA-B was observed when tmlU 
was expressed in-trans in P. fluorescens NCIMB 10586 WT. When expression was 
induced with 0.5 mM IPTG, all of the PA-B was found in the C5 form (Figure 4.2).  
 
Figure 4.2 HPLC and LC-MS chromatograms of P. fluorescens WT with pAMH1 
plasmid. A) Without IPTG induction, B) With 0.5mM IPTG induction. P. fluorescens and 
P. fluorescens (pJH10) are included as controls. All production cultures and HPLC 
analysis was performed in triplicate. Expression of TmlU causes a switch to truncated C5 
PA-B production. Integration of the peak areas is included in Appendix A. 
 
HPLC LC-MS 
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4.2.3 Effect of TmlU on P. fluorescens strains with single ACP (5, 6 or 7) deletions 
In analysing the possible explanations for the effect of TmlU there seemed to be 
two obvious possibilities.  First, the TmlU protein associates with MmpB in some way, 
and prevents it from undertaking more than one condensation.  Second, that the activity of 
TmlU off-loads the growing acyl chain early. Previous work by Ahmed Omer-Bali had 
started to explore the first of these possibilities, based on the hypothesis that perhaps it was 
the ACPs that were the target of TmlU binding, and that removal of a subset of the three 
ACPs in MmpB would result in loss of the sensitivity to TmlU.  Because there had been 
inconsistent results with the ACP deletion strains, HPLC analysis was performed on all the 
P. fluorescens strains with single deletions of ACP5, ACP6 and ACP7 (in triplicate) with 
and without IPTG induction. Wild type P. fluorescens NCIMB 10586 and wild type with 
pJH10 vector were used as controls. The HPLC chromatograms showed that TmlU still 
blocks mupirocin biosynthesis and causes the formation of the C5 version of pseudomonic 
acid B which can be detected at 14 min retention time. The results were the same when 
tmlU was induced with 0.5mM IPTG (Figure 4.3). 
Bioassays were performed using Bacillus subtilis 1064 as the sensitive bacterium, 
and plates of L-agar were supplemented with 0.5 mM IPTG to induce expression of the 
tmlU gene. Results in Figure 4.4 showed that clearing zone disappears completely when 
pAMHI was present in NCIMB10586∆ACP5 and NCIMB10586∆ACP7, while 
NCIMB10586∆ACP6 still formed a clearing zone although approximately 25% of the 
diameter of the wild type NCIMB10586(pAMHI). When tmlU expression from pAMH1 
was induced with IPTG a more drastic effect was seen (Figure 4.5). No clearing zone was 
observed in any of the strains with pAMHI.  
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Figure 4.3 HPLC chromatograms of NCIMB 10586 strains with single deletion in one of the 
MmpB ACPs (5, 6, or 7) with pAMH1 plasmid in-trans. NCIMB 10586 WT was used as a 
control. 
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Figure 4.4 Bioassay to show the effect of tmlU expression on strains of P. fluorescens 
with deletion in one of the ACPs (ACP5, ACP6, or ACP7) of MmpB. 
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Figure 4.5 The effect of in-trans expression of tmlU when induced with IPTG on P. 
fluorescens NCIMB 10586 strains with deletion in one of the ACPs (ACP5, ACP6, or 
ACP7) of MmpB. 
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4.2.4 Effect of point mutations on TmlU enzymatic activity and their impact on 
Mupirocin production 
The results obtained from the experiments designed to test the possible interaction 
between one of the ACPs in MmpB and TmlU were not conclusive enough to determine 
whether deletion of ACP6 is actually reducing the sensitivity towards TmlU. Therefore, it 
was decided to look at another aspect of this effect, namely the enzymatic activity of 
TmlU. It might be that this inhibitory effect is due to an enzymatic activity rather than a 
physical interaction between TmlU and part of MmpB.  
4.2.4.1 TmlU site directed mutagenesis 
To test this hypothesis, point mutations were made by site directed mutagenesis of 
different locations in the TmlU active site. Mutations of the amino acids were based on a 
sequence alignment of TmlU and firefly luciferase, which share a great deal of sequence 
and mechanistic similarities with peptide synthetases and acyl-CoA ligases (Figure 4.6). In 
the firefly luciferase, seven residues were found to be conserved and are likely to be 
significant in the process of binding ATP and adenylate formation: Gly200, Lys206, 
Glu344, Asp422, Arg437, Gly446 and Glu455 (Conti et al., 1996). The motif 198 [STG]--
STG-G-[ST]--TSE--[GS] xs-[PALIVM]-K206 is the signature sequence for the luciferase 
super-family. When Lys206 was mutated to arginine in firefly luciferase the acyl-CoA 
ligase activity decreased drastically, whereas changing other amino acids in the motif had 
a lesser effect. Another motif which seems to be of great significance for firefly luciferase 
is [STA]-[GRK]-D, and mutating Asp422 resulted in a complete loss of enzymatic activity 
(Conti et al., 1996). The locations of the TmlU mutations within a homology model of the 
structure are indicated in (Figure 4.7). 
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Figure 4.6 Sequence alignments of TmlU with amide synthetases and acyl-CoA 
synthetases showing the conserved amino acids in these proteins.  The boxed areas are the 
two motifs thought to be important for protein activity, and the red coloured residues 
represent the most conserved amino acids among the listed acyl-CoA synthetases. 1PG3: 
Acetyl CoA Synthetase, 3CW9: 4-Chlorobenzoyl-CoA Ligase and 3NYQ: Malonyl-CoA 
Ligase 
TmlU 
SimL 
NovL 
CouL 
CloL 
1PG3 
3CW9 
3NYQ 
TmlU 
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1PG3 
3CW9 
3NYQ 
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         Figure 4.7 A computational model of TmlU from Pseudoalteromonas 
SANK73390 showing the positions of the introduced mutations. The mutations 
are made in the acyl-activating enzyme consensus motif and it appears to be 
necessary for binding of ATP and adenylate formation. M1 (D422A) and M2 
(D422S) change the Aspartic acid (D) into Alanine and Serine respectively, while 
M3 (K206R) changes the Lysine in this motif to Arginine. This homology model 
was made by Jack Connolly, University of Birmingham. 
  
The Quick-change Lightning Site-Directed Mutagenesis Kit was used to introduce 
the required mutations into TmlU. Amplification of tmlU with the different point 
mutations was achieved using the primers listed in Table 2.8. The active site codon GAT 
encoding Aspartic acid in wild type was replaced by GCT encoding Alanine in mutant 
TmlUM1 (D422A), and to AGT in mutant TmlUM2 (D422S). The codon AAG encoding 
Lysine 206 was changed to AGG encoding Arginine in mutant TmlUM3 (K206R). The 
fragments were amplified, ligated into pET28a vector and sequenced to check for the 
mutations and then cloned into pJH10. 
M1 and M2  
M3  
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Before transforming E. coli S17-1 with the constructed mutants, the plasmids 
were checked for insert by restriction digest and sequencing. The plasmids pJH10-
TmlUM1, pJH10-TmlUM2 and pJH10-TmlUM3 were all digested with EcoRI and SacI to 
yield 1 kb and 1.96 kb inserts respectively (Figure 4.8). The reason for the different 
restriction pattern observed for pJH10-TmlUM1 compared with pJH10-TmlUM2, is that 
changing the amino acid from Aspartic acid to Alanine introduced a SacI restriction site 
almost in the middle of tmlU. This provided another method for checking that the mutation 
was there. 
 
5'-GTTGGTTAAATACCGGAGATCTTGGCAAGTTCGATGC-3' 
5'-GTTGGTTAAATACCGGAGCTCTTGGCAAGTTCGATGC-3' 
   
Figure 4.8 Analysis of the pJH-tmlU mutant expression plasmids.  The sequences 
above show how changing aspartic acid to alanine introduces a SacI site. Restriction digest 
analysis of: a) pET28a-TmlUM1, pET28a-TmlUM2 and pJH10-TmlUM3 digested with 
EcoRI and SalI; b) pJH10-TmlUM1, pJH10-TmlUM2 and pJH10-TmlUM3 digested with 
EcoRI and SacI. To confirm the size of the insert, the digestion products were run on a 1% 
agarose gel. 
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4.2.5 Effect of site directed mutagenesis of TmlU on its ability to interfere with 
Mupirocin production. 
A bioassay was conducted on the strains P. fluorescens NCIMB10586-pAMH1, 
P. fluorescens NCIMB10586-pTmlUM1, P. fluorescens-pTmluM2 and P. fluorescens-
pTmlUM3 in order to compare the effect of the mutant TmlU with wild type TmlU on the 
pseudomonic acid production. A large clearing zone can be seen when pTmlUM1 and 
pTmlUM2 were introduced into the wild type P. fluorescens NCIMB 10586. However, 
pTmlUM3 had the same effect as wild type TmlU in terms of blocking Pseudomonic acid 
A production. When the strains were induced with IPTG the clearing zone size decreased 
significantly (Figure 4.9 and Figure 4.10), which raised questions about whether the amide 
ligase activity of TmlU was deactivated. 
To confirm the results obtained from the bioassay, HPLC analysis was performed 
to verify the production of pseudomonic acid A in the different strains with and without 
IPTG induction. In contrast to the bioassay results, the IPTG induced P. fluorescens 
(pTmlUM1) and P. fluorescens (pTmlUM2) did produce pseudomonic acid A, which 
confirms that the amide ligase of TmlU was actually deactivated. Whilst P. fluorescens-
pTmlUM3 was consistent with the bioassay results, in producing the C5 version of 
pseudomonic acid B and not pseudomonic acid A (Figure 4.11). The disappearance or at 
least decrease in strength of the negative effect of TmlU on Pseudomonic acid A 
production in mutants M1 and M2, suggests strongly that the biochemical activity of TmlU 
is needed for the truncation of the pseudomonic acid A, consistent with the hypothesis that 
was being tested. This might therefore suggest that truncation of the pseudomonic acid is 
due to premature capture of the incomplete hydroxy fatty acid by TmlU.  If this is the case, 
then the normal thioesterase may not be needed for the release of the intermediate and this 
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would make a clear prediction – that loss of TE activity should have no effect on the TmlU 
effect. 
 
      
     
     
 
Figure 4.9 Bioassay to determine the effect of the mutations on mupirocin production  
as well as the enzymatic activity of TmlU. Bacillus subtilis was used as the test organism 
and P. fluorescens NCIMB 10586 was the producer organism. 
P. fluorescens WT P. fluorescens (pJH10) P. fluorescens (pAMHI) 
P. fluorescens (pTmlUM1) P. fluorescens (pTmlUM2) P. fluorescens (pTmlUM3) 
P. fluorescens (pTmlUM1)   P. fluorescens (pTmlUM2) P. fluorescens (pTmlUM3) 
+ IPTG + IPTG + IPTG 
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Figure 4.10 Quantitative bioassay of the NCIMB10586 WT expressing tmlU with 
different point mutations in the active site.  All the samples were repeated in triplicate. 
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Figure 4.11 HPLC chromatograms showing the effect of TmlU mutations on P. 
fluorescens WT with and without IPTG induction (panel A and B respectively). Panel C 
shows a 500mM PA.A standard. No quantification through peak integration was 
performed on these chromatograms, as the purpose was to detect presence or absence of 
PA.A only. 
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4.2.6 Investigating whether MmpB thioesterase is necessary for the effect of TmlU 
The current model for 9-hydroxynonanoic acid biosynthesis is that all the 
condensations occur on MmpB.  Given the results obtained in the previous section it 
seemed reasonable that deleting the TE domain may have no effect on TmlU mediated 
truncation PA-A.  This had already been tested based on a rather different hypothesis by 
(Omer-Bali, 2013) by deleting the thioesterase (TE) and introducing pAMHI to the P. 
fluorescens-mmpBΔTE. The results showed that deleting the TE in the wild type P. 
fluorescens abolished mupirocin production completely, and the same results were 
observed when tmlU was introduced to and expressed in P. fluorescens NCIMB10586-
mmpBΔTE.  
Deleting the thioesterase clearly prevented the premature release caused by TmlU.  
This means that either both the biochemical activity of TmlU and the TE domain of MmpB 
are required for premature release of the truncated PA-A/PA-B. Or that the effect of TmlU 
depends on its interaction with the TE domain, so that it is ready to capture the 
intermediate before release.  The hypothesis is that the TE domain is needed to tether 
TmlU in the right place in order for it to release the truncated pseudomonic acid (C5). A 
way to test this hypothesis would be to introduce mutations into the TE domain that knock 
out the biochemical activity but retain the domain structure, so that the TE-TmlU 
interaction can still occur if it is needed. According to the crystal structure of the 
thioesterase domain in fengycin biosynthesis cluster (Samel et al., 2006) the catalytic triad 
includes Serine84, Histidine201 and Aspartic acid111. Based on this model two single 
mutations were made in the TE domain of P. fluorescens - D111A and H201A (Figure 
4.12). The mutations were made by Splicing Overlap Extension technique (SOEing) 
explained in section 2.3.7 and illustrated in (Figure 2.1 and Figure 4.12b). The two TE 
mutations were cloned separately into pAKE604 generating two suicide plasmids 
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designated pTEMD (Figure 4.12c) and pTEMH. For the purpose of testing the interaction 
hypothesis tmlU, tmlUM1 and tmlUM2 were introduced to P. fluorescens strains with the 
mutated/inactive TE via conjugation, as explained in section 2.3.11.   
CTCCAGGCACGCGGACGCCAGGTGCAGTTGTTCATGCTCGACAGCTTTTTCTATGTGCCT 
L  Q  A  R  G  R  Q  V  Q  L  F  M  L  D  S  F  F  Y  V  P 
 
 
 
CTCCAGGCACGCGGACGCCAGGTGCAGTTGTTCATGCTCGCCAGCTTTTTCTATGTGCCT 
L  Q  A  R  G  R  Q  V  Q  L  F  M  L  A S  F  F  Y  V  P 
 
 
 
Figure 4.12 Construction of the D111A thioesterase point mutation to illustrate the 
method used. a) Locations of the D111A mutation in the TE domain, b) Schematic 
presentation of the SOEing PCR primers used to amplify TE with the required site directed 
mutations. c) Map of pTEMD showing the position of the inserted TE after amplification. 
The same method was used to generate plasmid pTEMH for the other mutation, H201A. 
c 
a 
b 
TE 
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Figure 4.13 Construction of the suicide plasmid pTEMD designed to introduce the 
TE point mutation D111A. a) The two amplified arms of TE produced by gradient PCR; 
b) The complete TE fragments after SOEing PCR; and c) The BamHI HindIII digestion of 
pAKE604 vector from different clones containing the TE mutated fragments. 
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4.2.7 Integrating the TE mutations into the P. fluorescens chromosome 
To facilitate the integration of the D111A and H201A mutations into the 
chromosome by homologous recombination, suicide vectors pTEMD and pTEMH were 
introduced into P. fluorescens strains, via conjugation from E. coli S17-1. After 
purification, the transconjugant cointegrant strains were grown without selection and 
plated on 5% sucrose plates to select for excisants, as the presence of the sacB gene which 
encodes the enzyme levansucrase, will not allow the bacteria to grow in the presence of 
sucrose because it catalyses levan synthesis which is lethal to the Gram negative cells.  
Therefore, the only bacteria that would survive are the ones without the integrated plasmid. 
The colonies obtained on the sucrose plates were patched onto Ampicillin and Kanamycin 
plates to check for plasmid excision (Figure 4.14) and section 2.3.11. 
 
Figure 4.14 Screening for potential mmpB TE point mutants. Ten colonies were 
patched on replica plates to identify excisants of each possible mutant (D=D111A and 
H=H201A) along with a non-mutated parental control strain (TE). Circled colonies were 
selected for sequencing as they did not grow on the kanamycin plate, which suggests that 
the plasmid had excised, and they may contain the correct recombinant. Only the 
sequenced strains with the correct recombinant were used in the downstream applications. 
Amp Kan 
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The hypothesis developed so far is that the inhibitory effect of TmlU depends on 
the interaction with the TE domain, so that it is ready to capture the intermediate before the 
release. This hypothesis is tested in this section through the introduction of point mutations 
to the TE domain designed to knock out its enzymatic activity, whilst keeping the domain 
itself intact so the protein-protein interaction can still take place. HPLC was used to detect 
the production of PA-A by the mutant strains and WT (Figure 4.15). H201A did not 
completely abolish PA-A production, suggesting some thioesterase domain activity was 
retained. No PA-A was detected with D111A suggesting that TE activity had been 
abolished. Therefore, all following experiments were carried out on the D111A mutant. 
P. fluorescens TE-D111A was transformed with pAMHI (expressing WT tmlU), 
pTmlUM1 and pTmlUM2, and analysed by HPLC to see if the presence of an 
enzymatically inactive thioesterase domain will allow TmlU to cause the release of the 
intermediate PA-B (C5) (Figure 4.16). In P. fluorescens TE-D111A (pTmlUM1) and 
(pTmlUM2), where both TmlU and the TE domain are enzymatically inactivated by point 
mutation, no release of PA-A or PA-B (C5) was observed. PA-B (C5) was observed in the 
wild type P. fluorescens with TmlU as expected, and P. fluorescens TE-D111A (pAMHI). 
The HPLC profile for the control strains was as expected in terms of the compounds that 
were eluted. 
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Figure 4.15 The effect of the TE point mutation. The HPLC chromatograph shows the 
effect of the two different point mutations on PA-A production.  
 
 
Figure 4.16 The effect of the TE-D111A point mutation on TmlU action. HPLC 
chromatograms showing production of PA-B (C5) when pAMHI is introduced to the P. 
fluorescens TE-D111A and P. fluorescens WT. P. fluorescens TE-D111A and P. 
fluorescens-pAMHI were used as controls. 
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4.2.8 Testing the interaction between Thioesterase and TmlU 
The results in the previous section (4.2.7) indicated that for PA-B (C5) to be 
produced, both an intact TE domain and an active TmlU are needed. This suggests that 
TmlU might interact directly with the TE domain. The bacterial two hybrid system 
(BACTH) was used in order to test this hypothesis. The principle of this method is 
described in section 2.5. The first step was to clone both the open reading frames for both 
the thioesterase of mmpB (designated te) and tmlU into pKT25 and pUT18 respectively. 
This was achieved using XbaI and HindIII for restriction digest and the resulting plasmids 
were designated pUT18tmlU and pKT25TE. These two plasmids were then co-
transformed into the host strain E. coli-BTH101. As a positive control, E. coli-BTH101 
was also transformed with the two plasmids pUT18-zip and pKT25-zip, as they express 
the fusion proteins which come together as a result the dimerization of the leucine zipper 
motif. As a negative control, E. coli-BTH101 was transformed with the empty pUT18 and 
pKT25 vectors.  
The bacterial strains were then plated on L-agar supplemented with 0.5mM IPTG 
and 40µg/ml X-gal, in addition to Ampicillin and Kanamycin for plasmid selection and 
incubated at 30°C for 24-72 hours. E. coli-BTH101 co-transformed with pUT18tmlU and 
pKT25TE produced blue colonies after 24 hours, while the negative strains produced 
lighter blue colonies. This suggested that there is an interaction as predicted. As an 
additional negative control E. coli-BTH101 was transformed with pUT18tmlU and pKT25, 
and pKT25TE with pUT18, both yielding light blue colonies. To check if TmlU behaves in 
the same way in its native system (the thiomarinol pathway), TmpB-TE (Figure 1.15) was 
also checked for interaction with TmlU. The results obtained were negative (Figure 4.17).  
To quantify and confirm the bacterial two hybrid results, β-galactosidase assays were 
conduct (Figure 4.18).  The results provided evidence that TmlU and MmpB-TE from the 
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mup cluster do interact. However, no interaction was detected between TmlU and TmpB-
TE from the pTMLI cluster, with a similar OD420 value to the negative control. 
 
Figure 4.17 The results of using the Bacterial two hybrid system to test for interaction 
between TmlU and MmpBTE.  a) BTH101 transformed with pUT18 and pKT25 vectors 
served as a negative control; b) BTH101 transformed with pUT18-tmlU and pKT25-TE 
which are the subject of the study; and c) the positive control where BTH101 strains were 
transformed with plasmids pUT18-zip and pKT25-zip 
 
 
 
Figure 4.18 Beta-galactosidase assay to quantify the level of interaction between TmlU 
and MmpB-TE and TmpB-TE. As a positive control E. coli-BTH101 was transformed 
with the two plasmids pUT18-zip and pKT25-zip that express the fusion proteins which 
come together as a result the dimerization of the leucine zipper motif. As a negative 
control, E. coli-BTH101 was transformed with pUT18 and pKT25. 
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4.2.9 Discussion  
Mutants of Pseudoalteromonas SANK73390, ∆tmpD (the largest PKS gene in the 
thiomarinol cluster) and ∆tmlU were previously examined for the potential of carrying out 
mutasynthesis. Feeding PA-A to ∆PKS mutants resulted in the formation of five different 
compounds: the pyrrothine derivatives of pseudomonic acid A and its 4-hydroxylated 
analogue, 4-hydroxypseudomonic acid A and two of 4-hydroxypseudomonic acid amides 
(Murphy et al., 2011). The ability of ∆PKS mutants to produce these compounds suggests 
that they are capable of adding pyrrothine to PA-A, in addition to catalysing its 4-
hydroxylation. Similarly, marinolic acid was produced in both the ∆NRPS and ∆tmlU 
strains, demonstrating the ability of TmlU and the 4-hydroxylase to accept thiomarinol 
analogues. So to further exploit the activity of tmlU, it was cloned into Pseudomonas 
fluorescens NCIMB10586 using the IncQ vector pJH10 under the control of the tac 
promoter and the lacIq gene (Murphy et al., 2011). When no IPTG was added to induce 
expression of tmlU a reduced amount of PA-A was produced. When tmlU expression was 
induced the C5 version of both PA-A and PA-B were produced.  
The observations made by Ahmed Omer-Bali, suggested that the ACPs of MmpB 
may be the point at which TmlU interacts with MmpB. To follow up on this hypothesis, 
tmlU was introduced to P. fluorescens strains with ACP (5, 6 and 7) single deletions. The 
purpose of this experiment was to investigate the position where TmlU interacts with 
MmpB. Hence, this test was designed to determine which one of the ACPs is the 
interaction point with TmlU. However, despite the initially promising results from Ahmed 
(Omer-Bali, A. 2013), the results presented in this thesis demonstrate that the absence of 
any of the ACPs in MmpB does not change the inhibitory effect of TmlU on PA-A 
production. All the strains with the single deletions did not produce any PA-A. However, 
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these results are not consistent with what was observed in the bioassays or with what was 
reported by (Omer-Bali, 2013).   
Because the results obtained from introducing tmlU to P. fluorescens-ΔACP6 
were inconsistent, we had to think of another way to understand the causes of this 
inhibitory effect. Given the 9-HN truncation observed with TmlU expression, it seemed 
logical that MmpB could be involved in causing this sensitivity to TmlU. Therefore, 
investigation into any protein-protein interaction between TmlU and any of the other parts 
of MmpB was undertaken. 
As deletions of different parts of in MmpB did not provide us with any clues 
regarding the inhibitory effect of TmlU, it seemed reasonable to test whether the 
enzymatic activity of TmlU is needed for inhibition, or if steric inhibition is sufficient 
(assuming that the mutation would not change the TmlU structure). The results obtained 
this experiment suggested that the activity of TmlU does play a role in causing the 
inhibitory effect as shown in Figure 4.11. Mutations 1 (D422A) and 2 (D422S) were 
observed to make P. fluorescens strains less sensitive to TmlU, however mutation 3 
(K206R) did not seem to affect TmlU enzymatic activity, and behaved as wild type TmlU 
by blocking mupirocin production. This could be explained by the location of both 
mutations 1 and 2 in the AMP binding sites, whereas 3 is not. 
Although very interesting, knowing that TmlU enzymatic activity is essential is 
only part of the puzzle, as it does not reveal which part of the biosynthetic pathway TmlU 
is interfering with. As previous results have demonstrated that the deletion of the mmpB-
TE abolished mupirocin production, it could be that the TE is needed for the release, but 
not its enzymatic activity. TmlU could be associated with TE to be ready to capture its 
substrate from MmpB at or before release. Thus, in order to test this hypothesis a point 
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mutation was made in the TE active site to deactivate its enzymatic activity, preferably 
without altering the TE domain structure.   
While introducing TmlU to P. fluorescens-mmpBΔTE did not release any product, 
introducing tmlU to P. fluorescens with point mutations to the TE domain did indeed result 
in production of the truncated product PA-B (C5). On the other hand, when the inactive 
TmlU was introduced to the point mutated TE strain, PA-B (C5) was not produced. This 
indicated that TmlU activity is critical for this process to take place, and so is the presence 
of the TE domain, as it may be needed to tether TmlU in the right place (Figure 4.16). 
To further investigate these predictions, the bacterial two hybrid system was used 
to test the interaction between TmlU and mmpB-TE. The results revealed that the TE and 
TmlU do seem to interact (Figure 4.17). When quantified by β-galactosidase assay (Figure 
4.18), a level of interaction significantly higher than the negative controls was observed. 
Although the data presented provided an explanation for a significant part of the TmlU 
inhibitory effect, it does not explain how exactly this process takes place. Previous work 
on the mupirocin pathway demonstrated that about 30% of PA-B gets converted into PA-A 
when P. fluorescens NCIMB10586 strains that cannot produce PA-B are fed with PA-B 
(Gao et al., 2014). This is also observed in P. fluorescens strains where the TE domain is 
deleted, which implies that the TE is not needed for the release of the substrate from 
mAcpE. In which case PA-B should be easily converted to PA-A if it was to be released 
into the cytoplasm by after MmpB action. One explanation could be that TmlU and MupU 
compete to bind the TE, and if the binding of MupU was not efficient it might affect the 
processing of the PA-B substrates. 
Previous experiments considered the possibility of MmpB being a dimer. In this 
scenario there would be two thioesterase domains in one complex. This hypothesis could 
126 
 
explain why we still see truncated versions of PA-A at a low TmlU level, as one of the TEs 
would be occupied with TmlU while the other is associated with MupU. This could mean 
that PA-B-CoA can be produced by TmlU, which is then used by MupU in order to load 
the mAcpE. When a high level of TmlU is expressed, this may lead to the occupation of 
both TEs by TmlU, preventing the efficient binding of MupU and processing to PA-A 
(Figure 4.19). 
In light of these findings we can conclude that the reason for TmlU interference 
with mupirocin biosynthesis is its interaction with the TE domain. This proved to be 
important not only for the release of the truncated product but also for tethering TmlU, 
allowing capture of intermediates. These results also represent the first strong evidence 
that MmpB makes the 9-hydroxynonanoic acid.  
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Figure 4.19 Schematic diagram showing putatively how TmlU affects the release of 
PA-A. The upper panel represents the wild type mupirocin tailoring pathway post MmpB. 
After release of the 9-HN intermediate catalysed by the MmpB TE domain, MupU loads 
the intermediate onto the discrete mAcpE, after which MupO, MupV, MupC and MupF 
complete tailoring to the final pseudomonic acid A product. The lower panel represents the 
hypothetical explanation for inhibition by TmlU. TmlU competes with MupU for binding 
the TE domains of the MmpB dimer. When TmlU binds it catalyses the premature release 
of truncated fatty acids. At low TmlU concentrations, sufficient MupU could bind the TE 
domain, explaining the various length PA-A forms observed. However, at high TmlU 
concentrations, MupU would not bind efficiently, explaining the observed switch to 
truncated PA-B forms. 
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5 Expressing the Hol genes from the thiomarinol cluster in P. 
fluorescens 
 
5.1 Introduction  
Polyketides and NRPS peptides constitute major classes of natural products that 
exhibit a wide range of biological activities, which makes them of great importance to our 
current pharmacopeia. Combinatorial biosynthesis studies have without doubt opened the 
door to discovering the endless potential of the natural products as antimicrobial 
compounds. With more polyketides and NRPS being discovered with unusual domains or 
new module organization, the manipulation of such diverse machinery is becoming a very 
attractive strategy for drug discovery purposes.  
In modular PKSs many of the techniques used to engineer the pathways are 
limited to individual domains or modules, while very few studies are involved in 
investigating the possibility of combining a whole protein subunit from different 
polyketides systems to create hybrid pathways with demonstrated therapeutic activities. 
Tang and coworkers applied this concept to Streptomyces lividans by co-transforming it 
with pikAI and pikAII which encode module 1 to 4 of picromycin, and the eryAIII and the 
eryAIII gene encoding subunit 3 which includes modules 5 to 6 of erythromycin (Tang et 
al., 2000). The result of this co-expression was a hybrid macrolactone 3-
hydroxynarbonolide. Daptomycin is an antibiotic that is produced by an NRPS in 
Streptomyces roseosporus. When the NRPS genes from related pathways were expressed 
in trans in a ΔNRPS Streptomyces roseosporus strain, a full complementation was 
achieved (Miao et al., 2006). These studies prove that entire subunits or a complete set of 
genes can be used successfully to engineer polyketide biosynthetic pathways and produce 
derivatives with improved therapeutic properties.  
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In the thiomarinol biosynthesis pathway there are seven ORFs that make up the 
NRPS gene cluster responsible for producing holomycin: holA (NRPS), holB 
(oxidoreductase), holC (thioesterase), holD (dehydrogenase), holE (acyltransferase), holF 
(oxygenase), and holG (decarboxylase) (Figure 1.15). Several experiments were conducted 
to test the possibility of creating new hybrid families using SANK73390 strains that 
harbour mutations or deletions in the NRPS genes. It was reported that ΔholA mutants 
could incorporate different pseudomonic acid metabolites or even amines such as 
anhydroornithine into the thiomarinol pathway, by accepting alternative substrates. This 
suggests that these NRPSs are flexible enough to be used for mutasynthesis studies 
(Murphy et al., 2011). As a proof of concept this chapter reports an attempt to express the 
genes for the entire NRPS subunit from SANK 73390 in trans in P. fluorescens NCIMB 
10586 to see if it is possible to create a thiomarinol–like hybrid using the mupirocin 
pathway rather than the marinolic acid pathway as the partner.   
5.2 Results 
5.2.1 Construction of pHolA-H 
 
Given the length of the entire hol genes fragment (~11 kb) and to avoid 
introducing any errors during the amplification process, it made sense to divide the hol 
genes into three pieces. These were amplified separately and then assembled into one 
vector. In pTML1, there appear to be five transcriptional units (tmlT to tmlN, tmlM to 
tacpB, tmlA to tmlF, tmlY to tmlP and tacpA to holH). This suggests that the hol genes are 
likely to be transcribed from one promoter as one operon, and so it should be feasible to 
express all of them under control of the tac promoter (Fukuda et al., 2011). The natural 
ribosome binding sites (RBS) were used for cloning of all the hol genes. The 5.8 kb 
segment encoding the NRPS genes designated Hol1 was amplified using primers as shown 
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in Table 2.9, and cloned into the vector pGEM-T-Easy, (Figure 5.1a). The ligation was 
achieved by A-tailing the Hol1 fragment so it could be inserted between the 3´-T 
overhangs at the insertion site of pGEM-T-Easy generating the plasmid pGEMHol1. An 
important part of the strategy is that the fragment is flanked by the restriction sites XhoI 
and AgeI to allow the sub-cloning in the next stage of this process. 
In a similar manner pGEMHol2 was produced by amplifying 3.25 kb of the 
NRPS genes and ligating it into the vector pGEM-T-easy. The Hol2 DNA fragment is 
flanked with sites for the restriction enzymes AgeI and AvrII.  
The next step after constructing pGEMHol1 and pGEMHol2 was to insert both of 
Hol1 and Hol2 fragments into one plasmid. SbfI cuts pGEM-T-Easy vector at the 
nucleotide 89, so pGEMHol1 was digested with AgeI and SbfI, while Hol2 was cut out of 
pGEMHol2 using the same restriction enzymes AgeI and SbfI as shown in Table 2.5. The 
resulting plasmid, which includes both Hol1 and Hol2 was named pGEMHol12. The third 
segment (Hol3 fragment) which constitutes 3.16 kb of the NRPS genes was designed to be 
flanked by AvrII and BstbI restriction sites and was cloned into pGEM-T-easy vector in the 
same way as the Hol1 and Hol2 fragments to produce the plasmid pGEMHol3. 
In order to assemble all the fragments into one vector, Hol3 was cut out of 
pGEMHol3 using restriction sites AvrII and SbfI, and ligated into pGEMHol12 which had 
been digested with the same enzymes, producing pGEMHol123 (Figure 5.1b). To transfer 
all the genes that make up the hol NRPS from SANK 73390 into the expression vector 
pJH10 as a single piece, pJH10 was digested with XhoI and ClaI, while Hol123 was cut 
out using XhoI and BstbI (which has ends compatible with ClaI) and the DNA ligated. The 
plasmid produced, designated pHOLA-H, was quality checked by digest and sequencing 
(Figure 5.1c).  
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5.2.2 Insertion of tmlU into the pHOLA-H expression plasmid 
 
To create a hybrid pathway between holomycin and mupirocin, it is important to 
have the putative amide ligase TmlU present. Therefore, tmlU was amplified and cloned 
into pHOLA-H between the sites AbsI and PacI to create pHolA-HtmlU. 
 
Figure 5.2 Map of the expression plasmid pHolA-HTmlU. A tmlU fragment was cloned 
into pHolA-H between the AbsI and PacI sites. 
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Figure 5.3 Verification of pHOLA-HtmlU by colony PCR.  
 
5.2.3 Expression from pHOLA-HtmlU in P. fluorescens NCIB10586 
 
Using the conjugation method explained in section 2.3.11, pHolA-HtmlU was transferred 
from E. coli S17-1 to P. fluorescens NCIB10586, both to determine any phenotypic effect of the 
hol-genes (pyrrothine) on P. fluorescens, and whether or not expressing pyrrothine genes would 
give rise to a new compound as a result of creation of a hybrid pathway. The thiomarinol NRPS 
part produces holomycin, which belongs to the pyrrothines. A key feature for the pyrrothines is the 
yellow pigment they produce, responsible for the bright yellow phenotype of SANK 73390 
(Shiozawa et al., 1993). However, the obtained transformants looked white in colour despite 
containing pyrrothine genes as shown in (Figure 5.4). 
 
Figure 5.4 Phenotype comparison of a) SANK 73390 WT and b) P. fluorescens (pHOLA-
H). 
5 kb 
1 kbkb 
Hol1 Hol2   Hol3 
tmlU 
a b 
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5.3 Discussion  
The growing number of the biologically active compounds that are built up of 
hybrid pathways, provide diverse platforms to engineer novel metabolites. This applies in 
particular to engineering hybrid polyketide-peptide biosynthetic pathways starting from the 
many biosynthetic clusters that have been cloned and characterised. However, although the 
available biochemical and genetic data allow us to predict the function of domains and 
modules for both PKS and NRPS, there is still relatively little known about how domains 
and modules interact with each other.  This makes the mission of creating new hybrids and 
effective pathways more challenging.  
In P. fluorescens, one way to explore the potential of making a hybrid pathway is 
to test the possibility of expressing a set of genes in the mupirocin producer strain. If 
correctly expressed P. fluorescens might be able to produce both mupirocin and 
holomycin, and the presence of these two biosynthetic pathway may give a rise to a new 
compound which is a hybrid between the two as in the case of the thiomarinol system. This 
approach will also add to our knowledge of how these systems work and how flexible they 
are. 
Many recent studies investigated the possibility of creating a hybrid scaffold by 
merging two pathways; an interesting observation is that both PKSs and NRPSs utilize a 
similar strategy to synthesise different classes of natural products (Du et al., 2001). In one 
of the studies, the Tylosin polyketide synthase (Tyl PKS) was produced in a Streptomyces 
venezuelae strain that lacks the pikromycin PKS gene cluster. The mutated Streptomyces 
venezuelae not only produced tylactone (a 16-membered ring macrolactone), but also 
produced a small amount of desosamine-glycosylated tylactone, which proved the 
possibility of creating a hybrid molecule (Jung et al., 2006). On a smaller scale, the ACP 
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of the actinorhodin polyketide synthase was swapped with ACPs from other pathways 
such as the granaticin, oxytetracycline and tetracenomycin pathways. These all produced 
aromatic polyketides similar to actinorhodin, and it was also observed that some ACP 
regions are interchangeable, yielding functional hybrid ACPs (Khosla et al., 1993). 
Although swapping and replacing domains in PKSs is a common practice to achieve a 
hybrid pathway, this nevertheless highlights the fact that building blocks from different 
biosynthetic pathways can be used to construct a functional hybrid compound. However, 
one of the best demonstrations of creating hybrid pathway was conducted in an E. coli 
strain, where different components from different biosynthetic systems have been 
expressed together. These components included, for example, a phosphopantetheinyl 
transferase gene from Bacillus subtilis, genes responsible for the methylmalonyl-CoA 
extender unit from Streptomyces coelicolor and many more required to make a complete 
and functional biosynthetic pathway. This eventually resulted in production of the 
expected compound from entirely hybridized machinery (Kinghorn et al., 2009).  
The mupirocin and thiomarinol pathways share many features both structural and 
functional, and the idea of assembling parts of both into one hybrid pathway could be 
feasible, given the successful outcome of the previously conducted studies. The problem 
with cloning an entire functional pathway is that the antibiotic produced by that particular 
set of genes might be toxic to the bacterial cell, which makes it challenging to express. In 
this case the NRPS genes from the thiomarinol pathway encode the pyrrothine production 
pathway, which potentially could be harmful to P. fluorescens.  However, transfer of the 
pHolA-H genes to P. fluorescens was successful, although the observed transfer frequency 
was low. While the colonies obtained contained the plasmid pHolA-H, the observation that 
they did not produce the yellow pigmentation characteristic of pyrrothines suggests the hol 
genes were either not expressed correctly, or not processed to the active form. In the 
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mupirocin biosynthetic pathway there are eleven type I ACPs in addition to five type II 
ACPs (mAcpA-E). ACPs rely on post-translational modification to convert the apoACP 
into the active holo-form. This process is catalysed by a phosphopantetheinyl tranferase 
(PPTase) and involves the attachment of a phosphopantetheine prosthetic group to a 
conserved serine residue. The role of the ACP in this process is to hold the acyl 
intermediates attached to the thiol of the phosphopantetheine moiety, which in turn 
supplies the KS active sites and some other catalytic domains with the necessary 
substrates. Three types of PPTases can be found based on sequence and ACP specificity: 
the first is the AcpS type of Escherichia coli which is normally responsible for the 
modification of ACPs of primary metabolism. The second type is related to the surfactin 
synthase PPTase of Bacillus subtilis and modifies carrier proteins in secondary metabolic 
pathways, including the ACPs in PKSs and NRPSs pathways. The third group of PPTases 
are found integrated as domains in multifunctional type I proteins and are usually found in 
fungal type I FASs (Lewis Mander, 2010, Shields et al., 2010).  
Given that TmlN and MupN appear to be homologous (Figure 5.5), there was 
potential that MupN would convert the apoACP into the active holo-form through its 
phosphopantetheinyl transferase activity. However, given the lack of holomycin 
production in the P. fluorescens NCIMB10586, it may be that the hol ACPs specifically 
require TmlN (putative phosphopantetheinyl tranferase). If this were the case, then in order 
for the different parts of this assembly and especially the hol genes to be correctly 
processed after expression, a functional tmlN would be needed. Future work would 
therefore be to add this to the system to see if this achieves the desired functional hybrid 
pathway. Therefore, tmlN could be cloned into another, compatible vector such as pJS701, 
which is an IncP-9 expression plasmid. The effect of the presence such a vector co-
maintained with pHolA-H in terms of pyrrothine production is yet to be determined.  
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Figure 5.5 Alignment of MupN from the mup cluster and TmlN from the pTML1.  
MupN is thought to be a Phosphopantetheinyl transferase. The sequence shows that TmlN 
might have the same function as MupM since they seem to have conserved areas. 
 
 
 
 
 
 
 
 
 
 
 
 
MupN 
TmlN 
MupN 
TmlN 
MupN 
TmlN 
MupN 
TmlN 
139 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 
 
 
 
 
 
 
 
 
 
 
140 
 
6 Attempts to bypass KS2 gatekeeper activity in the mup cluster 
 
 
6.1.1 Introduction  
Many steps of the mupirocin biosynthesis pathway have been elucidated, however 
some features of the mup cluster are still ambiguous as to the way mupirocin is 
synthesised. In this regard, tailoring regions in the mupirocin biosynthesis pathway are yet 
to be fully characterised, despite the insight gained from previous knock-out studies 
(Hothersall et al., 2007). While trying to identify the gene responsible for the 6-
hydroxylation of monic acid, one possible candidate considered by Dr. Joanne Hothersall 
at the University of Birmingham (personal communication) was mupA. MupA is predicted 
to introduce the hydroxyl group at C6 based on its similarity to proteins such as OnnC and 
PedJ from the onnamide and pederin pathways respectively, in which they are proposed to 
add a hydroxyl group at C7. Considering the position of the 6-OH group in the backbone it 
could not be added until after the condensations performed by MmpD.  The first module of 
MmpD joins carbons 14-13 to 12-11 plus carbon 17 due to the alpha methyl addition 
(bearing in mind the numbering system is in reverse order compared to the direction of 
synthesis). The second module adds carbons 10 and 9, the third adds carbons 8 and 7 plus 
the carbon 16 due to alpha methyl addition, whilst the fourth adds carbons 6 and 5.  Thus 
the earliest that 6-hydroxyation could occur is after the condensation performed by module 
4.  Moving to MmpA, the KS of module 1 is predicted to be non-elongating (KS0) because 
of its sequence family, and because only two further elongations are needed to complete 
the monic acid backbone which are performed by MmpA modules 2 (adding carbons 4 and 
3) and 3 (adding carbons 2 and 1 as well as carbon 15 of the beta-branch methyl group), 
(Figure 6.1) (Haines et al., 2013).  
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Figure 6.1  Biosynthetic pathway for PA-A showing mupirocin H production when 
HCS is inactivated. a) Proposed biosynthetic pathway of monic acid and the formation of 
mupirocin H. ACP domains ACP2 and ACP3 are involved in the third module of MmpA. 
The red dots represent the position of C3 in pseudomonic acid as it progresses through the 
biosynthetic pathway. b) Proposed biosynthesis of mupiric acid. Adapted from (Haines et 
al., 2013). 
 
Mupirocin H, the intermediate released in elevated quantities when the mupH encoding 
part of the beta-branching cassette is mutated, depends on the presence of the 6-OH as part 
of the off-loading and ring formation. So we can also deduce that the 6-OH must have 
been added at an earlier stage, shortly after the addition of carbons 6 and 5.  One 
possibility is that it happens on the non-elongating module of MmpA and since mupA is 
located immediately adjacent to it, there would be a sort of genetic logic that would make 
this a neat hypothesis. To test this hypothesis mupA was deleted and also point mutations 
were made in the active site of mupA (G127A, D134A) by Dr. Joanne Hothersall. LC-MS 
was performed by our collaborators in the University of Bristol to identify the secondary 
metabolites produced by the mutant strains. This revealed that the strains with deleted 
mupA produced mupiric acid but interestingly no mupirocin H, while the ones with point 
mutations in mupA had a similar profile to the P. fluorescens wild type.  
A B 
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The interesting observation here is that when mupA is deleted no other 
intermediates longer than mupiric acid were produced, which suggests that MupA is acting 
after MmpD. In the same way accumulation of mupirocin H indicates that the mutated 
protein acts at some point after the MupH cassette. This deletion has also shown that the 
intermediates lacking the α-hydroxyl produced by P. fluorescens ΔmupA cannot go beyond 
or past MmpD. In this chapter, we investigate whether mupA is in fact responsible for 
adding this α-hydroxyl, and if yes, what makes the 6-hydroxylated intermediates capable 
of proceeding further in the biosynthetic pathway, compared to the non-hydroxylated 
intermediates?  
In many trans-AT PKSs, the KS is proposed to play the role of gatekeeper by 
transferring specific intermediates through the assembly line (Gay et al., 2013) (Nguyen et 
al., 2008).  Assuming that this is the case with the KS-mupA2 (in the second module of the 
MmpA subunit), it is possible that this KS is specific for α-hydroxylated intermediates, 
hence it does not allow any non-hydroxylated intermediates to pass through.  To test this 
hypothesis Dr. Rohit Farmer at the University of Birmingham performed a docking study. 
A homology model of KS-mupA2 dimer was generated to imitate the decarboxylation 
stage of the Claisen condensation, where the substrate is attached to the catalytic cysteine 
in the KS active site, and the malonate is attached to the phosphopantetheine arm of the 
ACP (Figure 6.2 and Figure 6.3).  
An interesting observation is that a DNYK motif seems to be conserved between 
the KSs in MmpA and TmpA, but not in the other KSs (Figure 6.4). This observation led 
to the idea of swapping the KS-mupA2 loop with the loops from KS-mupA1 and KS-
mupA3 as these two do not require an α-hydroxylated substrate and might allow the 
pathway to continue. 
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Figure.6.3 A close up view of the DNYK motif which is shown in pink coloured sticks 
(Dr. Rohit Farmer – University of Birmingham) 
 
 
Figure 6.4 Alignment of the KS domains from the mup cluster and the tml cluster showing 
the conserved motif in MmpA and TmpA which was swapped in KS-mupA2 (in the 
second module of the MmpA) with KS-mupA1 and KS-mupA3. 
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6.2 Results 
6.2.1 Experimental design 
As explained in section 6.1.1 the idea was to replace the KS2-MmpA loop with 
the KS1-MmpA and KS3-MmpA loops in both the P. fluorescens wild type and P. 
fluorescens ΔmupA, (Figure 6.5). The primers were designed to be suitable for the SOEing 
PCR method, such that the loops from KS1-mmpA and KS2 mmpA were included in the 
primers as shown in Table 2.10. 
 
 
Figure 6.5 The KS2 -mupA amino acids highlighted in yellow were replaced by the loops 
of KS1-mmpA and KS3-mmpA highlighted in green. 
 
 
Following a successful amplification, the required fragment was cloned into 
pAKE604 suicide vector in order to integrate the replaced loops into the chromosomal 
DNA of P. fluorescens ΔmupA (Figure 6.6). The chromosomal integration method and 
suicide vector excision are described in detail in section 2.3.11.  
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Figure 6.6 (a) Multiple pAKEKS1 clones digested with EcoRI and HindIII to check if it 
contains the ks1-mmpA fragment; (b) Replica plating to screen for excision of the suicide 
plasmid; and (c) Colony PCR of P. fluorescens to check if that integration has taken place.  
 
  
a 
b 
c 
Kan Amp 
ks1-mmpa 
1kb 
EcoRI/HindIII digest of pAKEKS1 clones 
#1          #2         #3        #4 
PCR of colonies to check for integration 
#1    #2     #3    #4   #5    #6    -ve 
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6.2.2 Analysis of products 
 
The hypothesis was that MupA hydroxylates pseudomonic acid at the 6-OH 
position. Deletion of mupA results in production of mupiric acid only, which is produced 
by MmpD, implying that the chain cannot pass through KS2-MmpA and the pathway is 
somehow blocked. It was hypothesized that the KS2 loop specificity for hydroxylated 
products is the reason for this blockage, and if the loop was replaced with loops from other 
KSs like KS1-MmpA or KS3-MmpA this would solve the issue, as these KSs do not 
require α-hydroxylated substrates to pass the growing chain. Therefore, it was logical to 
expect the new product to be more hydrophobic than pseudomonic acid A and hence it 
would elute later than 20 minutes (PA-A retention time). P. fluorescens ΔmupA-(KS1) and 
P. fluorescens ΔmupA-(KS3) were analysed by HPLC to check for pseudomonic acid A 
derivatives along with relevant controls (Figure 6.7). As expected the strain with the 
deleted mupA did not produce pseudomonic acid A, while the strain with the replaced loop 
(KS2 loop swapped with KS1 loop) P. fluorescens ΔmupA-KS1 did produce a new peak 
with a retention time of 22-23 minutes (Figure 6.7 a). However, this was later identified by 
LC-MS as a non-pseudomonic acid product by our collaborators in Bristol. The KS2 loop 
swap was also done in the P. fluorescens WT and the resultant product had a similar 
profile and retention time to P.  fluorescens ΔmupA-KS1 (Figure 6.7 b). 
The strain P. fluorescens ΔmupA-KS3 where the KS2 loop was replaced with the 
KS3 loop was also analysed by HPLC but the results were different to those from the P. 
fluorescens ΔmupA-KS1 as there was no product at all, and the HPLC traces looked quite 
similar to the P. fluorescens ΔmupA. KS3 loop was also introduced to the wild type P. 
fluorescens and the same results were obtained (Figure 6.8). 
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Figure 6.7 HPLC analysis of a) P. fluorescens ΔmupA-KS1 and b) P. fluorescens-KS1 , P. 
fluorescens WT and P. fluorescens ΔmupA were used as controls. 
 
P. fluorescens WT 
PA-A 
PA-A 
mupA-KS1P. fluorescens 
mupAP. fluorescens 
P. fluorescens WT 
P. fluorescens-KS1 
P. fluorescens ΔmupA 
a 
b 
 
Non-pseudomonic acid 
Non-pseudomonic acid 
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Figure 6.8 HPLC traces of P. fluorescens ΔmupAKS3  P. fluorescens WT and P. 
fluorescens ΔmupA were used as controls. 
 
6.3 Discussion  
Mupirocin biosynthesis is thought to begin with creation of the C12 pentaketide 
moiety by MmpD. The basis for this deduction goes back to the accumulation of mupiric 
acid by a mutant P. fluorescens strain with a deletion in the KR of MmpD domain 4. This 
observation meant that the intermediate produced was not able to carry on through the 
biosynthetic pathway to the stage of a fully formed monic acid.   
In order to study the biosynthetic pathway of Mupirocin and identify genes and 
proteins involved in the pathway several deletions and mutations have been made. For this 
Chapter the mutation(s) of interest were created by Dr. Joanne Hothersall, with the aim of 
identifying which part of the cluster is responsible for adding the 6-hydroxyl group.  Given 
the position of this α-hydroxyl it was proposed that mupA, which is a tailoring gene in the 
mupirocin biosynthetic pathway, might be responsible for this hydroxylation as discussed 
PA-A 
P. fluorescens WT 
P. fluorescens ΔmupAKS3 
P. fluorescens ΔmupA 
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in the introduction. Therefore, a mutant strain of P. fluorescens was created with mupA 
deleted.  
The results obtained from analysing P. fluorescens NCIMB10586 ΔmupA with 
HPLC confirmed that, consistent with the proposal, the only product released by the 
mutant was mupiric acid, which is a shunt product released by module 4 of MmpD. With 
that in mind the next step mainly revolved around testing whether MupA is in fact a 
hydroxylase, and if so what is preventing a non-hydroxylated product from continuing on 
down the assembly line, which is the case when mupA is deleted. One explanation would 
be that if MupA is acting as a hydroxylase, the non-hydroxylated substrate resulting from 
mupA deletion would not be recognized by the KS in MmpA. Hence the chain would not 
be extended to proceed to the next module. 
An example of trans-AT ketosynthase intolerance is the KS5 of the bacillaene 
pathway, which does not accept an acyl chain with methyl branching at the β-position. 
This was demonstrated to be due to a key residue in BaeL-KS5 which controls KS5 
tolerance to branching. The sequence of Bael-KS5 was compared to another 150 KSs 
domains from various trans-AT PKSs. Sequence analysis revealed that the presence of Gly 
and Ala is crucial for accepting the carbon branch in the acyl chain (Kohlhaas et al., 2013).  
KS specificity in PKS systems has been an interesting research area recently, and 
with the advancing computational studies a lot has been revealed regarding the basis of the 
KS specificity and how it works. However, when it comes to bioengineering, functional 
testing is still a necessity to understand the rules of rational engineering of the different 
PKS systems (Hertweck, 2015).  
The computational modelling of the KS-mupA2 revealed the unique motif DNYK 
which is conserved in both MmpA and TmpA but not in the rest of the KSs of either 
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pathway. However, when P. fluorescens-ΔmupA KS3 and P. fluorescens-ΔmupA KS1 were 
analysed by HPLC the obtained peaks were non-pseudomonic acid derivatives, which 
suggested that the pathway is still blocked. The only piece of information we have 
regarding the 6-hydroxylation is that the gene responsible for it is most likely to be acting 
after MmpD. In addition to MupA there is another candidate that could add the hydroxyl 
group, MupL (a putative hydrolase), and so to see the effect of swapping the loops we 
need to introduce the non-hydroxylated substrate into P.fluorescen ΔmupL. Future work 
will need to address this issue further. 
 
 
 
 
 
 
 
 
 
 
 
152 
 
 
 
 
 
 
 
 
 
Chapter 7 
 
 
 
 
  
 
 
153 
 
7 General Discussion 
 
7.1 General outlook 
With the inevitable rise of resistance against the current and the future antibiotics, 
it is critical to find ways to keep up with the rapidly evolving bacteria and slow down the 
selective pressure which is not only dangerous but also costly. One of the successful 
strategies to produce new antibiotics was to use old antibiotics as a scaffold through 
synthetic tailoring.  Microbial natural products played a major role in the resurgence of 
antimicrobial agent production, and since their discovery in the 1950s polyketides remain 
an important driving factor in the process of discovering new sources of antimicrobial 
compounds. Therefore, the subject of this thesis is highly relevant to the current issue of 
antibiotic resistance and trying to revive the field of drug discovery with not only new 
antimicrobial compounds, but also new classes of antibiotics by exploiting the potential of 
polyketides to provide us with a vast range of new molecules through molecular 
engineering and mutasynthesis. 
7.2 Discussion of key conclusions 
7.2.1 Genes simL, clouL, couL and novL could be used in engineering P. fluorescens to accept 
different precursors  
It has been proven by (Anderle et al., 2007a) that polyketide synthases can be 
tolerant of accepting different precursors such as in the case of the aminocoumarins but it 
has also been shown that similar proteins are not guaranteed to have similar effects on a 
particular pathway regardless of their structural and functional resemblance. This was 
evident when CloL and CouL, which share 91% sequence identity, were found to be very 
different when it came to substrate specificity. While CouL accepted a wide range of 
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substrates and was rather promiscuous, CloL showed a very strict selectivity for substrates 
and very few were accepted. This promiscuity of at least some of these different amide 
ligases encouraged us to hope that they would work to join aminocoumarin to mupirocin 
or marinolic acid.  Although it looks like simL, couL, cloL and novL have no negative 
effect on Mupirocin production, they do cause some sort of change in the pathway 
particularly simL and cloL.  Looking at the HPLC traces in (Figure 3.8) we notice that in 
the case of cloL and simL the PA-A peak starts to decrease when the concentration of the 
aminocoumarin is increased, but the same cannot be said about couL where the PA-A peak 
seems to be unaffected by the aminocoumarin concentration. It might be that both cloL and 
simL are actually incorporating aminocoumarin into the mupirocin pathway, hence the 
disappearance of the PA-A peak. However, as there are no obvious new peaks in any of 
the fed strains there is still the possibility of needing another enzyme in order for the amide 
synthetases to be processed or accept other substrates, as is the case with TmlU and HolE 
(Section 4.1). More research is needed to identify the observed peaks and whether they are 
a result of successful substrate incorporation or if we need to include an additional enzyme 
into the feeding method to facilitate this process. 
7.2.2 Can an entire set of genes from the thiomarinol biosynthetic pathway be cloned and 
expressed in trans? 
Chapter 5 of this thesis describes the cloning of the full set of hol genes from 
thiomarinol biosynthetic pathway and their expression in-trans in P. fluorescens 
NCIMB10586 that produces mupirocin. The ability to successfully do this should provide 
us with new insight into mutasynthesis, especially if it had been possible to show that the 
hol genes are responsible for producing holomycin, thus representing the possibility of 
creating a product similar to thiomarinol in case this approach had been successful.  
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The genes involved were cloned sequentially, keeping their natural RBSs intact. 
When the hol genes were introduced to P. fluorescens the colonies looked like typical P. 
fluorescens colonies without the yellow pigmentation expected if they were producing 
pyrrothine. It is a possibility that pyrrothine is not being produced due to the absence of 
tmlN which is the putative phosphopantetheinyl tranferase. This problem could be solved 
by cloning tmlN on a different expression vector. Another hurdle to be passed might be the 
survival of P. fluorescens itself, since producing pyrrothine might be toxic for the cells in 
which case tmlM should be included in the experimental design as it is the equivalent of 
mupM, the gene responsible for producing mupirocin-resistant IleS2.  
7.2.3 Protein-protein interaction might be the reason behind the inhibitory effect of TmlU 
on mupirocin production 
Regardless of whether TmlU works alone to join holomycin and marinolic acid 
together or the whole process is performed using TmlU and HolE, the fact that introducing 
tmlU to the wild type P. fluorescens stops full length mupirocin from being produced 
demonstrates again that PKSs, although flexible to a certain extent, are more complex than 
our current ideas suggest, and proves that we still have not unlocked some of the rules that 
control the biosynthetic pathways. Chapter 4 of this study sheds the light on some of the 
dynamics involved in accepting and offloading intermediates in the mupirocin biosynthetic 
pathway.  
From the results obtained in Chapter 4 it is evident that TmlU is somehow 
obstructing the normal flow of events in the Mupirocin biosynthetic pathway. More 
particularly it seems like tmlU is blocking the second and the third round of condensation 
which prevents the conversion of the 3-hydroxypropionic acid to 9-hydroxynonanoic acid. 
Inactivation of the CoA ligase in TmlU by point mutations revealed that the enzymatic 
activity is required for release of the truncated products. Further investigation has also 
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shown that releasing the intermediate requires the thioesterase TE to be present as no 
product was released when TE was deleted, despite tmlU being expressed in-trans. When 
the thioesterase was inactivated by point mutations and tmlU was introduced to the P. 
fluorescens strain, the C5-PA-B reappeared, which suggested the possibility of a protein – 
protein interaction. This observation drew attention to the fact that both TmlU and TE need 
to be intact even if not enzymatically active in order for the truncated product to be 
released, and TmlU may well be associated with TE to be ready to capture its substrate 
from MmpB at or before release. Further investigation confirmed the possibility of 
interaction by using the bacterial two hybrid system followed by the β-galactosidase assay. 
The hypothesis formulated based on the results of this chapter proposes that the TE is 
necessary for the TmlU effect to take place, perhaps because it tethers TmlU in the right 
place to release the C5-PA-B. There is also the possibility of MupU being involved in this 
inhibitory effect especially in situations where TmlU levels are low. In the latter scenario 
one TE of the dimer may be occupied by MupU while the other is occupied by TmlU, 
which could explain in a way why we still get the truncated PA-A even with TmlU 
present. In this case TmlU will compete with MupU to be tethered to TE which results in 
TmlU processing a truncated intermediate (Figure 4.19). The results presented in this 
chapter are the most important part of this thesis and represent a very significant step 
towards a better understanding of the biosynthetic pathway of mupirocin and how to 
improve our strategies to create a hybrid molecule using mupirocin as a scaffold. 
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7.3 Future work 
Creating effective hybrids requires a good understanding of the rules governing 
interactions between polyketide modules. Although most of the mupirocin biosynthetic 
pathway has been elucidated, there are still parts of this system that need more research in 
order to successfully incorporate new molecules into the pathway. Feeding different 
compounds to P. fluorescens strains can be very useful, but more input is required as to at 
which stage this will result in a successful incorporation.  There is also the issue of which 
gene will catalyze the joining of two different molecules. These questions could be 
addressed by trying feeding at different intervals or possibly trying other amide ligases 
from different pathways.  
In order to express a gene correctly all the elements involved should be 
incorporated, and in case of cloning the hol genes there are still missing pieces in this 
construct that are needed to produce pyrrothine. TmlN is the equivalent of MupN in the 
mup cluster. MupN has been proved to be essential to activate the ACPs of primary 
metabolism in the mupirocin biosynthetic pathway, it is therefore possible that providing 
the Hol genes with their own PPTase is critical to their function, and so cloning tmlN is the 
next step to do in order to try to activate the construct pHolA-H (Shields et al., 2010).  
However, fitness cost is one of the main concerns in studies like this as the main fragments 
are cloned into a 13 kb vector, while the fragment itself is about 11 kb which brings the 
entire plasmid size to almost 25 kb. Adding TmlN and TmlM will obviously add to this, so 
the aim should be to clone the two genes into the same vector (pJS701) which is 
compatible with pJH10-based plasmids.  
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In regards to the KS2 loop specificity, the hypothesis was built on the basis that 
mupA is involved in hydroxylating pseudomonic acid A at the carbon 6 position. As 
replacing the KS2 loop with loops from both KS1 and KS3 did not result in the pathway 
going any further, it is possible that mupA does not do what we predicted it to do and in 
fact if these loops were introduced into a strain like P. fluorescens ΔmupL, the pathway 
might actually pass this bottleneck as mupL is a putative hydrolase. 
Since it has been recently found that TmlU is in fact a CoA-ligase that needs the 
acyl transferase HolE to join the two parts of thiomarinol together, it might be feasible to 
check if HolE also interacts with thioesterase or if it is only TmlU that does this. 
Previously complementation studies were carried out to test if tmlU could complement P. 
fluorescens ΔmupU  based on weak similarities (Fukuda et al., 2011); although tmlU did 
not complement mupU, it would be interesting to see if MupU and the MmpB TE interact. 
This could give us a better picture about where and how TmlU is interacting within the 
mupirocin biosynthetic pathway, through its similarity with MupU as it is proposed that 
MupU transfers the growing polyketide chain to the mAcpE. This could be achieved by 
using either the bacterial two hybrid system or possibly co-purifying the TE with TmlU 
and MupU separately, as it would serve as a more solid proof that these two proteins do 
interact. 
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Appendix A 
Integrated HPLC peak areas.  
All production cultures and HPLC analysis was performed in triplicate. The peak areas 
listed below are the average of these triplicates, ±SEM (standard error of the mean). 
Fig 3.3 (PA.A) peak area integration 
Strain  Mean ± SEM (V2) 
P. fluorescens wt 34.72±1.15 
P. fluorescens pJH10 78.18±9.17 
P. fluorescens pJH10 SimL 40.53±1.75 
P. fluorescens pJH10 NovL 130.55±9.94 
P. fluorescens pJH10 CloL 98.20±1.70 
P. fluorescens pJH10 CouL 125.55±7.52 
 
Fig 3.5 Thiomarinol peak area integration 
Strain Mean ± SEM (V2) 
SANK73390 wt 30.82±0.42 
SANK73390 pNOVL 27.62±0.44 
SANK73390 pSIML 27.96±0.53 
SANK73390 pCLOL 26.96±0.29 
SANK73390 pCOUL 26.92±1.44 
 
Fig 4.2 (PA.A C5) peak area integration 
Strain  Mean ± SEM (V2) 
P. fluorescens pAMHI 102.67±4.32 
P. fluorescens pAMHI+IPTG 36.43±1.53 
 
Fig 4.3 (PA.A C5) peak area integration 
Strain  Mean ± SEM (V2) 
P. fluorescensΔACP5  pAMHI 113.08±3.34 
P. fluorescensΔACP6  pAMHI 84.87±1.38 
P. fluorescensΔACP7  pAMHI 81.43±0.33 
 
 
 
 
